

TOMULEASA / Ciprian**Address:** Mircea Eliade No 28 Street, Cluj Napoca, Judet Cluj, Romania**Email:** ciprian.tomuleasa@umfcluj.ro**Citizenship:** Romanian**Date of Birth:** July 24th, 1986**Place of Birth:** Piatra Neamt, Romania**Professional experience:**

Period	Position held / occupation	Employer
2023 - present	Research Professor	Medfuture Research Center Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
2025 - present	Associate Professor	Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
2022 - present	Senior consultant in hematology	Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania
2017 - present	General Secretary of Hematology Committee, affiliated with the Romanian Health Ministry	Health Ministry of Romania
2021 - present	General Secretary of Cellular Therapies Committee, affiliated with the Romanian Health Ministry	Health Ministry of Romania
2017 - 2022	Attending physician in hematology	Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania
2017 - 2025	Lecturer in hematology	Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
2020 - 2023	Research Associate Professor	Medfuture Research Center Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
2015 - 2020	Research Assistant Professor	Research Center for Functional Genomics, Biomedicine and Translational Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
2013 - 2016	Resident physician in hematology	Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
2013 – 2015	Physician Scientist	Research Center for Functional Genomics, Biomedicine and Translational Medicine,

		Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
2011 - 2013	Postdoctoral Fellow	Department of Internal Medicine, Division of Gastroenterology and Hepatology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA
2009 - 2011	Research Teaching Assistant	Department of Histology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
2007 - 2011	Research Assistant	Department of Immunology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania

Education and Training:

Period	Position	Institution	Type of training	Supervisor
2018, September	Visiting Physician	Department of Immunotherapy, National Cancer Center Tokyo, Japan	Training in immunotherapy for hematological malignancies	Professor Shigehisa Kitano
2017, October	Visiting Physician	Department of Stem Cell Transplantation, National Cancer Center Tokyo, Japan	Training in the clinical management of complications following allogeneic stem cell transplantation	Professor Yoshihiro Inamoto
2017, November	Visiting Physician	Department of Stem Cell Transplantation, Osaka International Cancer Center, Osaka, Japan	Training in allogeneic stem cell transplantation for T-cell malignancies	Professor Shigeo Fuji
2016 - 2017	EHA fellow	European Hematology Association	Training in clinical research and clinical trials	Scientific Board of the European Hematology Association
2015, June - October	Visiting Physician	Department of Stem Cell Transplantation and Cellular Therapies, University of Texas MD Anderson Cancer Center, Houston, USA	Training in haploidentical stem cell transplantation	Professor Stefan Ciurea

2014, June - October	Visiting Physician	Department of Stem Cell Transplantation and Cellular Therapies, University of Texas MD Anderson Cancer Center, Houston, USA	Training in allogeneic stem cell transplantation	Professor Stefan Ciurea
2013 - 2016	Resident Physician	Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania	Residency in hematology	Dr. Delia Dima / Professor Andrei Cucuianu
2011 - 2013	Ph.D. student	Department of Immunology, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania	Ph.D. in cancer immunology	Professor Victor Cristea
2011 - 2013	Postdoctoral Fellow	Department of Internal Medicine, Division of Gastroenterology and Hematology, The Johns Hopkins University School of Medicine, Baltimore, USA	Postdoctoral research in tumor biology	Professor Florin Selaru
2005 - 2011	Medical student	Faculty of Medicine, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania	M.D. studies	Faculty of Medicine
2001 - 2005	Highschool student	Calistrat Hogas National College, Piatra Neamt, Romania	Baccalaureate diploma	Highschool studies

Meaningful Accomplishments in Medicine:

- The **in vitro isolation of the first cancer stem cell line from Romania**, in March 2010, as a 4th year medical student (**Tomuleasa C, Soritau O, Rus-Ciuca D, et al.** Isolation and characterization of hepatic cancer cells with stem-like properties from hepatocellular carcinoma. *J Gastrointestinal Liver Dis.* 2010; 19(1):61-7).
- **Part of the team that has successfully carried out the first haploidentical stem cell transplantation in Romania**, in collaboration with the transplant unit from Fundeni Clinical Institute, in February 2015, as a 3rd year resident physician in clinical hematology (Tanase A, Tomuleasa C, Colita A, Ciurea SO. Haploidentical donors: can faster transplantation be life-saving for patients with advanced disease? *Acta Haematologica* 2016, 2016;135(4):211-6/ Tanase A, Tomuleasa C, Colita A, Ciurea SO. First successful haploidentical stem cell transplantation in Romania. *Rom J Intern Med* 2016, 2016 Sep 1;54(3):194-20.

- **Joint research publications with a Nobel Prize laureate.**
 1. KRAS/NRAS/BRAF mutations as potential targets in multiple myeloma. Sergiu Pasca, Ciprian Tomuleasa, Gabriel Ghiaur, Delia Dima, Vlad Moisoiu, Cristian Berce, Cristina Stefan, **Aaron Ciechanover**, Hermann Einsele. *Frontiers in Oncology*, 2019, 9:1137.
 2. Targeting ubiquitination in myeloid malignancies. From basic research to drug discovery in MDS and AML. Rares Drula, Sabina Iluta, Diana Gulei, Delia Dima, Cristina Iuga, Anca Dana Buzoianu, Gabriel Ghiaur, **Aaron Ciechanover**, Ciprian Tomuleasa. *Blood Reviews*, 2022.
 3. Insights into the roles of ubiquitin ligase KPC1: from cell cycle control to NF-kB regulator. Diana Gulei, Rares Drula, Gabriel Ghiaur, Anca Dana Buzoianu, Ciprian Tomuleasa, **Aaron Ciechanover**. *Cancer Research*, 2023.
 4. The NF-kB subunit generated by KPC1-mediated ubiquitination and proteasomal processing suppresses tumor growth. Yelena Kravtsova-Ivantsiv, Gilad Goldhirsh, Ciprian Tomuleasa, Eli Pikarsky, **Aaron Ciechanover**. *Cancer Cell International* 2023.
 5. Proteasome inhibition in combination with immunotherapies: state-of-the-art in multiple myeloma. David Keyes, Diana Gulei, Rares Drula, Diana Cenariu, Bogdan Tigiu, Delia Dima, Alina Tanase, Sorina Badelita, Anca-Dana Buzoianu, Stefan Ciurea, Gabriel Ghiaur, Evangelos Terpos, **Aaron Ciechanover**, Hermann Einsele, Ciprian Tomuleasa. *Blood Reviews*, 2023.
 6. Targeting degradation of IKZF1 and IKZF3 through modulation of the E3 ligase substrate in the context of cellular therapies for multiple myeloma. David Keyes, Anamaria Bancos, Adrian Bogdan Tigiu, Ioana Rus, Delia Dima, Diana Cenariu, Madalina Nistor, Diana Gulei, Alina Tanase, Anca Colita, Anca Buzoianu, Cristina Iuga, Mihnea Zdrengeha, Evangelos Terpos, Stefan O. Ciurea, **Aaron Ciechanover**, Hermann Einsele, Ciprian Tomuleasa. *Biomarker Research* 2025.
 7. Proteolysis targeting chimeric-based technology in myeloma and lymphoma. Tigiu AB, Ivancuta A, Tomuleasa C, Nistor M, Keyes D, Cenariu D, Munteanu R, Buzoianu AD, Einsele H, Federico M, Kobold S, Gulei D, **Ciechanover A**. *Molecular Cancer Therapeutics* 2026

- Member of the **World Health Organization Strategic Advisory Group of Experts on In Vitro Diagnostics** (Geneva, 2020).

- Member of the **European Principles of Haemophilia Care Update Working Group**, responsible for writing the principles of management of patients with hemophilia (Dublin, 2026)

- **Hirsch Index – 35 (Scopus) ; 41 (Google Scholar)**

Meaningful Awards:

- **Medical Student of the Year Award**– 2008, awarded by the Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania.
- Ion Baciú Award, to the **Ph.D. Thesis of the Year** – 2012, awarded by the Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania.
- Rezident de Nota 10, to **Best Resident Physician in Romania** – 2013, awarded by the Victor Babes University of Medicine and Pharmacy Timisoara, Romania.
- Octavian Fodor Award for Clinical Activity – 2024, awarded by the Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca, Romania
- Gandit in Romania Award for scientific activity – 2024, awarded by the Romanian Academy of Scientists

- **International Project of the Year**, awarded by the Novo Nordisk Haemophilia Foundation (Zurich, Switzerland) with the project Strengthen hemophilia care in the north and establish a national registry in Romania – 2022.
- **Best Poster Presentation Award**, Nordic Coagulation Meeting, Helsinki, Finland, 2024.

Member of Professional Societies:

Professional Society	Period	Type of membership
European Hematology Association	2014 - present	Member
American Society of Hematology	2014 - present	Member
Romanian Society of Hematology	2017 - present	Member
Romanian Society of Radiotherapy and Medical Oncology	2008 - present	Member
Romanian Society for Bone Marrow Transplantation	2016 - present	Founding member
Japanese Society of Hematology	2019 - present	Member
British Society of Haematology	2025 - present	Member

Active Participant, with oral communications or poster presentations:

National Scientific Events: 36 meetings

International Scientific Events: 42 meetings in Australia (Melbourne), Austria (Vienna), Belgium (Antwerp), China (Beijing), Croatia (Zagreb), Cyprus (Nicosia), Czech Republic (Brno), Denmark (Copenhagen), Egypt (Cairo), France (Angers, Bordeaux, Champéry, Paris), Germany (Berlin), Greece (Ioannina), Hungary (Budapest, Pecs, Szeged), Germany (Berlin, Jena, Lindau), Iceland (Reykjavik), Italy (Bologna, Milano, Rome, Viareggio, Florence), Japan (Osaka, Tokyo), Lithuania (Druskininkai), Moldova (Chisinau), the Netherlands (Duin en Kruidbergweg), Poland (Poznan, Krakow), Portugal (Faro), Romania (Bucharest, Cluj Napoca, Iasi, Poiana Brasov, Piatra Neamt, Predeal, Sinaia, Timisoara, Tulcea), Russia (Moscow), Serbia (Novi Sad), South Africa (Cape Town, Stellenbosch), Spain (Barcelona, Madrid, Sitges, Valencia), Switzerland (Geneva), Taiwan (Taipei), Turkey (Istanbul) United Kingdom of Great Britain (Edinburgh, London) and United States of America (Atlanta, Boston, Baltimore, Honolulu, Houston, Orlando, San Diego, San Francisco).

Invited Speaker / Physician / Scientist:

Stellenbosch University, Stellenbosch, South Africa- November 2016

University of the Western Cape, Cape Town, South Africa – February 2017

People's Liberation Army Navy Hospital, Beijing, China – September 2017, October 2019

National Cancer Center, Tokyo, Japan – October 2017

Osaka International Cancer Center, Osaka, Japan – October 2017

University of Iceland, Reykjavik, Iceland – March 2018

Reykjavik University, Reykjavik, Iceland – May 2021

Ohio State University, Columbus, OH, USA – December 2021

de Duve Institute, Université Catholique de Louvain, Brussels, Belgium – December 2024

International scientific recognition :

- Moderator for the Session on CAR T Cells on the Pipeline – 5th European CAR T Cell Meeting. Rotterdam, The Netherlands, February 9th-11th, 2023
- Invited Speaker for the Session of Ultrarare Diseases – 21st European Congress of Internal Medicine. Athens, Greece, March 15th-18th, 2023.

- Invited Speaker and Moderator – Red Talks. Implementing prophylaxis in the low resource setting. Istanbul, Turkey, May 30th-June 1st, 2024.
- Speaker – Oral Presentation – European School of Hematology. 5th How to diagnose and treat multiple myeloma. Vienna, Austria, April 3rd-5th, 2025.
- Invited Speaker - AHP Masterclass - Advancing patient care in AHP, Athens, Greece, May 26th, 2025
- Invited Speaker – National Oncology Meeting, Chisinau, Moldova, October 10th, 2025
- Invited Speaker and Moderator – Red Talks. Implementing prophylaxis in the low resource setting. Istanbul, Turkey, October 31st, 2025.
- Invited Speaker – Annual National Meeting of the Czech Society of Hematology, Prague, Czech Republic, January 22nd, 2026

Research grants coordinated:

No.	Funding mechanism	Projects	Position	Period	Partner budget (EURO)
1	Grant received after the Romania – European Economic Space (EES) International Research Grant Competition 2014-2016	Nanotechnology approach in Acute Myeloid Leukemia management – Collaboration with Norway (University of Bergen) – acronym: NanoLAM	Grant manager for the partner institution - Ion Chiricuta Oncology Institute (Principal investigator – Prof. Andrei Cucuianu, Iuliu Hatieganu University of Medicine and Pharmacy Cluj Napoca). Co-principal investigator: Prof. Emmet McCormack – University of	2014-2016	110.000

			Bergen, Norway		
2	Internal Grant Competition of the Iuliu Hatieganu University of Medicine and Pharmacy, for young researchers, 2014-2015	Cell and molecular mechanisms of primary myelofibrosis	Principal investigator - Iuliu Hatieganu University of Medicine and Pharmacy	2014-2015	8.000
3	Grant received after the Romania–European Economic Space (EES) International Grant Competition 2015-2016	Innovative Nanoparticles-based Chemotherapy for Acute Myeloid Leukemia - Collaboration with Norway (University of Bergen) – acronym: NanoChemotherapy	Principal investigator - Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Emmet McCormack – University of Bergen, Norway	2015-2016	41.000
4	Grant received after the Young Research Team Competition, awarded by the Romanian Research Ministry and Education 2016-2017	Massively parallel high-throughput DNA sequencing for the identification of microRNAs differentially expressed between the metastatic site and the tissue of origin in cancers of unknown primary site	Principal investigator - Iuliu Hatieganu University of Medicine and Pharmacy	2016-2017	125.000
5	Internal Grant Competition of the Iuliu Hatieganu	A synthetic lethality approach in the acute myeloid leukaemia chemotherapy: PARP	Grant mentor for Grigore Gafencu	2015-2016	2.000

	University of Medicine and Pharmacy, for medical students, 2015-2016	inhibitors plus anthracycline plus decitabine vs anthracycline plus decitabine –in vitro efficacy testing			
6	Internal Grant Competition of the Iuliu Hatieganu University of Medicine and Pharmacy, for medical students, 2015-2016	The efficacy of pirfenidone in primary myelofibrosis	Grant mentor for Sonia Selicean	2016-2017	2.000
7	Grant resgna;ceived after the Romania - P.R. China International Bilateral Collaboration competition 2016-2017	Invasive biomarkers for graft versus host disease following bone marrow hematopoietic stem cell transplantation	Principal investigator- Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Jianlian Shen – Navy General Hospital, Beijing, China	2016-2017	9.533
8	Grant received after the FDI competition of the National Council for the Financing of University Education 2017	Modern training for healthcare professionals affiliated to the departments of hematology, oncology and bone marrow transplantation	Principal investigator- Iuliu Hatieganu University of Medicine and Pharmacy	2017	43.826
9	Grant received after the FDI competition of the	Correlation of the educational curricula in molecular medicine and	Principal investigator- Iuliu Hatieganu	2018	38.922

	National Council for the Financing of University Education 2018	translational oncology with the European workforce demand	University of Medicine and Pharmacy		
10	Grant received from the National Research Ministry for Frontiers Research 2017-2022	Multifunctional magnetoplasmonic nanoparticles for point of care applications in acute myeloid leukemia, acronym: NanoTEX	Grant manager for Ion Chiricuta Oncology Institute. (Principal investigator: Prof. Emil Burzo, Babes Bolyai University Cluj Napoca, Romania)	2018-2022	180.000 (total grant value – 1.800.000)
11	Invited Professor 2018 Grant – Gabriel Ghiaur, Johns Hopkins University School of Medicine, from the National Research Ministry	Invited Professor Grant – Gabriel Ghiaur, Johns Hopkins University School of Medicine.	Principal investigator, for the Iuliu Hatieganu University of Medicine and Pharmacy.	2018	2.619
12	Grant received after the Romania - P.R. China International Bilateral Collaboration competition 2018-2019	Experimental Immunotherapy for hematological malignancies	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Liren Qian, Navy General Hospital, Beijing, China	2018 - 2019	8.609

13.	Grant received after the FDI competition of the National Council for the Financing of University Education 2019	Increase of the competitiveness of medical education by correlating the curricula to Anglo-Saxon standards	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy	2019	41.916
14.	Grant received after the Romania–European Economic Space (EES) International Grant Competition – Collaboration with Iceland; 2020-2022	HE-RO-IS strategic collaboration in hematology – Iceland collaboration (Reykjavik University) – Acronym: HERO	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Olafur Eysteinn Sigurjonsson, Reykjavik University, Iceland	2020 - 2021	144.153
15.	Novo Nordisk Haemophilia Foundation International Grant 2020-2022	Strengthen haemophilia care in the north and establish a national registry in Romania – Romania 3	Principal investigator, Romanian Hematology Society	2020 - 2021	81.903
16.	Grant received from the National Research Ministry for Postdoctoral Research 2020-2022	Evaluation of the effect of human chorionic gonadotrophin in stem cell transplantation as a new method of pretransplant mobilization	Grant mentor for Andrei Cismaru - MD, PhD, Iuliu Hatieganu University of Medicine and Pharmacy	2020 - 2022	51.667
17.	Grant received from the National Research Ministry	New generation preclinical model for evaluating the therapeutic	Grant mentor for Diana Gulei - PhD, Iuliu	2020 - 2022	51.667

	for Postdoctoral Research 2020-2022	role of microRNA-505-5p for metastasis limitation in melanoma	Hatieganu University of Medicine and Pharmacy		
18.	Grant received from the National Research Ministry for Young Research Teams 2020-2022	Supporting a team of young researchers in creating an independent research program based on the use of the Sleeping Beauty protocol for developing CAR T cells – Acronym: SEATTLE	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy	2020 - 2022	93.001
19.	Grant received after the Romania – Wallonia/Belgium International Bilateral Collaboration competition 2020-2022	Consolidation of the Wallonia-Romania collaboration for setting of new standard operation procedures (SOP) in immunotherapy	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Jo Caers, University of Liege, Belgium	2021-2022	10.561
20.	Grant received from the National Research Ministry for Exploratory Research 2020-2023	Harnessing the ubiquitin-proteasome system (UPS) to suppress tumor's growth via manipulating generation of NF-kB – Acronym: ROME	Co-principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Principal investigator: Prof. Aaron Ciechanover – Nobel Prize in Chemistry 2004	2021-2024	250.000
21.	Grant received from the National Research Ministry	The role of stromal CYP26 in retinoid homeostasis in the	Co-principal investigator, Iuliu Hatieganu	2021 - 2024	250.000

	for Exploratory Research 2020-2023	context of myelodysplastic syndromes pathogenesis and response to treatment Acronym: LONDON	University of Medicine and Pharmacy. Principal investigator: Prof. Gabriel Ghiaur		
22.	Novo Nordisk Haemophilia Foundation International Grant 2022-2024	Strengthen haemophilia care in the north-eastern part of Romania and in Moldova and establish a registry in Moldova – Romania 4	Principal investigator, Romanian Hematology Society	2022 - 2024	102.779
23.	Grant received from the National Health Ministry, for providing outreach healthcare services to vulnerable population from isolated areas 2022-2023	Sequencing as standard-of-care in diagnosis of hemophilia and rare coagulation disorders in Romania	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Grant director: Romanian Hemophilia Association (Mr. Daniel Andrei)	2022 - 2023	222.222
24.	Grant received from the Romanian Academy of Science	Mathematical model for clonal hematopoiesis	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy.	2023-2024	10.000
25.	Grant received from the European Hematology Association	CAR NK-cells for tumor-associated macrophage immunomodulation – a new era of immunotherapy	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy.	2024	20.000

26.	Grant received from the Romanian Government, National Plan for Resilience (PNRR)	Creating a Research Group of Excellence to develop cell and immune therapy technology to target the tumor microenvironment	Co-principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Principal investigator: Prof. Hermann Einsele	2024-2026	996.125
27	Grant received from the National Research Ministry for bilateral research with Moldova	Collaborative RO MD research on diagnosis, prognosis and treatment strategies for patients with HIV (+) DLBCL	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy.	2024 - 2025	142.835
28.	Grant received from the National Research Ministry – Henri Coanda Award	Genomic, transcriptomic and metabolomic evaluation of resistance to venetoclax in acute myeloid leukemia	Grant mentor for David Kegyés - MD, Iuliu Hatieganu University of Medicine and Pharmacy	2024	20.000
29.	Grant received after the Romania – Wallonia/Belgium International Bilateral Collaboration competition 2024-2025	RNA methylation as a prognostic factor in myelodysplastic syndromes treated with azacytidine	Principal investigator, Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Stefan Constantinescu, Catholic University of Louvain, Belgium	2024 - 2025	10.000

30.	Grant received from the European Commission – the MSCA Doctoral Network	Advancing in the challenge of improving Lymphoma and Leukemia Survival	Grant Manager for the Iuliu Hatieganu University of Medicine and Pharmacy. Co-principal investigator: Prof. Laura Belver, Josep Carreras Leukemia Institute, Barcelona, Spain	2025-2028	246.245 (out of 4.251.582)
Total amount of continuous funding between 2014 - present					3.316.583 EURO

Editorial experience:

2018 – present, editorial board – Medicine and Pharmacy Reports.

2018 – present, editorial board – Journal of Clinical Medicine, impact factor: 5.688.

2019 – present, editorial board – Annals of Translational Medicine, impact factor: 3.689.

2019: Invited editor for a special issue: Frontiers in Pharmacology, impact factor: 3.92

2020: Invited editor for a special issue: Frontiers in Medicine, impact factor: 5.091

2021: Invited editor for a special issue: Frontiers in Medicine, impact factor: 5.091

2025: Invited editor for a special issue: Frontiers in Medicine, impact factor: 3.5

Coordinator of M.D. / Ph.D. thesis / postdoctoral research for.

M.D. students.

No.	Student name	Thesis title	Year of graduation
1.	Patric Teodorescu	Algorithm of diagnosis for cancers of unknown primary site	2017
2.	Daiana Temian	The role of epigenetics in breast cancer	2018
3.	Alexandra Sacu	Role of microRNA-19b in the progression of chronic lymphocytic leukemia into Richter syndrome	2018
5.	Katharina Vogel	Pulmonary complications following chemotherapy in hematological malignancies	2019
6.	Vlad Moisoiu	Mathematical modelling for the response to therapy in chronic myeloid leukemia	2019
7.	Wilhelm-Thomas Micu	The role of CYP26A4 in the bone marrow niche for acute promyelocytic leukemia	2019
8.	Sergiu Pasca	The use of bioinformatics for sub-classifying acute myeloid leukemia	2020
9.	Gina Dobie	Role of RAMAN spectroscopy in T cell lymphomas	2020
10.	Jerome Dobrowolski	The role of basophilia in chronic myeloproliferative disorders	2020
11.	Ioana Pustan	Management of central venous approach for the immunocompromised patient	2020
12.	Cedric Richlitzki	Correlation between T-cell lymphoma and alcohol	2021
13.	Sebastian Rauch	Development of a mouse model of acute myeloid leukemia	2021
14.	Elena-Maria Santa	The role of MEWS score in hematological patients eligible for ICU transfer	2021

15.	Anthi Sarika	EuroFlow flow cytometry for chronic lymphocytic leukemia	2021
16.	Jakob Dominicus Anton Steinheber	Role of SERS spectroscopy in the differential diagnosis of CNS involvement for hematological malignancies	2021
17.	Elias Alexander von Gamm	The role of epigenetics in Down Syndrome-associated acute leukemia	2022
18.	Rebecca Waniek	Preclinical mouse model for acute myeloid leukemia	2022
19.	Mihnea Micu	Prognostic role of accompanying T cells associated with the tumor microenvironment in MALT lymphomas	2022
20.	Cristina Ciulavu	Management of patients with rare hematological malignancies infected with SARS-CoV-2 virus, under therapy with monoclonal antibody-based drugs	2022
21.	Raymond Nagy	The role of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia	2022
22.	Julianne Maria Barth	Autopsy results in COVID-19 patients	2024
23.	David Kegyes	The role of tumor microenvironment in the development of extrinsic resistance to venetoclax in acute myeloid leukemia	2025

Ph.D. thesis.

No.	M.D. name	Clinical residency	Title of the Ph.D. thesis	Year of graduation
-----	-----------	--------------------	---------------------------	--------------------

1.	Valentina Sas	Pediatrics	Genetic mutations in Down syndrome-associated dyserythropoiesis and dysmegakaryopoiesis	2021
2.	Catalin Constantinescu	Anesthesiology – Intensive Care	Management in the intensive care unit of patients with hematological malignancies, following immunotherapy and stem cell transplantation	2022
3.	Minodora Desmirean	Pathology	The role of biotechnology in the diagnosis and prognosis of T-cell lymphomas	2022
4.	Dalma Deak	Hematology	Molecular mechanisms of central nervous system dissemination of acute leukemias	2024
5.	Sabina Iluta	Hematology	Age-related clonal hematopoiesis in hematological malignancies	2025
6.	Ioana Tichil	Plastic and reconstructive surgery	Transfusion characteristics for the plastic and reconstructive surgery patient	2024
7.	Ciprian Jitaru	Hematology	Use of the resources of the Romanian medical system in treating hematological malignancies	Still in training
8.	Tanase Timis	Medical Oncology	Molecular therapies with therapeutic purpose in malignant melanoma	Still in training

9.	Maria Santa	Hematology	Modern approach in hemophilia management	Still in training
10.	Anamaria Bancos	Hematology	Molecular aspects in central nervous system involvement for hematological malignancies	Still in training
11.	Raluca Munteanu	Animal facility	Etiopathogenetic mechanisms in cancer	2024
12.	Radu Tomai	Hematology	Use of CAR T cells for targeting the tumor microenvironment	Still in training
13.	David Kegyes	Hematology	Mechanisms of resistance to venetoclax and personalized therapies in hematological malignancies	Still in training

Postdoctoral researchers

No.	M.D. name	Clinical residency	Title of the postdoctoral research	Period
1.	Andrei Cismaru	Medical Oncology	Evaluation of the effect of human chorionic gonadotrophin in stem cell transplantation as a new method of pretransplant mobilization	2020 - 2022
2.	Diana Gulei	Biochemistry	New generation preclinical model for evaluating the therapeutic role of microRNA-505-5p for metastasis limitation in melanoma	2020 - 2022

Experience in clinical research and clinical trials

(in blue – completed; in red – ongoing, in yellow - enrolling)

No.	Disease	Title	Sponsor / International investigator / Period	Role in the study
1.	FLT3-positive acute myeloid leukemia, frontline	Phase III clinical trial investigating quizartinib plus standard chemotherapy versus standard chemotherapy , for patients with therapy-naïve FLT3-IDT positive acute myeloid leukemia	Daiichi-Sankyo, 2018-2020	Co-investigator for Ion Chiricuta Oncology Institute Cluj Napoca (Principal investigator: Dr. Delia Dima)
2.	Therapy-naïve T-cell lymphomas	Prospective, longitudinal, multinational registry of patients with newly diagnosed peripheral T cell lymphoma	Associazione Angela Serra per la Ricerca sul Cancro Centro Oncologico Modenese - Medical Oncology, School of Medicine	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca

			University of Modena and Reggio Emilia Modena, Italy, 2018 - present	
3.	Paroxysmal nocturnal hemoglobinuria, frontline	A phase III randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB12 and eculizumab in subjects with paroxysmal nocturnal hemoglobinuria	Samsung Bioepis, 2019- 2022	Co- investigator for Ion Chiricuta Oncology Institute Cluj Napoca (Principal investigator: Dr. Delia Dima)
4.	Acute myeloid leukemia, unfit	Real world treatment patterns and clinical outcomes in unfit AML patients receiving first line systemic treatment or best supportive care (study H19-743)	Abbvie, 2019-2020	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
5.	Mantle cell lymphoma, unfit	A Phase 3 Randomized, Open-Label, Multicentre Study Comparing Zanubrutinib (BGB- 3111) plus Rituximab Versus Bendamustine	BeiGene, 2023 - present	Co- investigator for Ion Chiricuta Oncology Institute Cluj Napoca

		plus Rituximab in Patients with Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation		(Principal investigator: Dr. Delia Dima)
6.	Therapy-naïve primary myelofibrosis	A Phase 3 Randomized, double-blind, active-control study of CPI-0610 and ruxolitinib versus placebo and ruxolitinib in JAKi treatment naïve MF patients (MANIFEST-2)	Constellation Pharmaceuticals, 2021 - 2022	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
7.	Hematological malignancies	Evaluation of the safety of pegfilgrastim in the primary prophylaxis of febrile neutropenia in patients with myelosuppressive chemotherapy	Totem Communication, 2022	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
8.	Hemophilia A	A multinational, open-label, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors (FRONTIER-2)	Novo Nordisk Pharmaceuticals, 2022 - 2024	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca

9.	Relapsed/ refractory follicular lymphomas	Towards personalized medicine for refractory/relapsed Follicular Lymphoma patients: the Cantera/Lupiae registry	European Hematology Association (EHA) Lymphoma Group, 2022 – present	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca
10.	Primary myelofibrosis	A multi-country, real-world study to explore treatment patterns, effectiveness and healthcare resource utilization for patients diagnosed with myelofibrosis through chart review (METER)	Abbvie, 2022	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca
11.	Polycythemia vera	A Prospective, Multicenter, Non-interventional, Observational, Post-authorization Safety Study of Ropoginterferon alfa-2b in Polycythemia Vera Patients (Besremi-PASS)	AOP Orphan, 2022 - present	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca
12.	Relapsed / refractory multiple myeloma	A phase 3, two-stage, randomized, multicenter, open label study comparing CC-92480, bortezomib and	Bristol Myers Squibb, 2023-present	Principal investigator for Ion Chircuta Oncology

		dexamethasone (480 Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma.		Institute Cluj Napoca
13.	Relapsed / refractory follicular lymphoma and marginal zone lymphoma	A retrospective multicenter, non-interventional study to generate a real-world comparator cohort in adult patients with relapsed or refractory follicular lymphoma and marginal zone lymphoma	Bristol Myers Squibb, 2022	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
14.	Frontline, primary myelofibrosis	A Phase 1b, Open-Label, Dose-Finding Study to Assess the Safety, Tolerability, and Preliminary Efficacy of BMS-986158 Monotherapy and in Combination with Either Fedratinib or Ruxolitinib in Subjects with DIPSS-Intermediate or High Risk Myelofibrosis	Bristol Myers Squibb, 2023 - 2024	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca

15	Frontline, MPN-associated fibrosis	A phase I, double-blind, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with myeloproliferative neoplasm-associated myelofibrosis on concomitant JAK2 inhibitor therapy and who require red cell transfusions	Bristol Myers Squibb, 2023 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
16.	Relapsed/refractory paroxysmal nocturnal hemoglobinuria	A phase 1b, proof-of-concept study for the evaluation of safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of OMS906 for patients with nocturnal paroxysmal hemoglobinuria	Omeros, 2023	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
17.	Mature B-cell malignancies	A phase 1, open label, multicenter, dose-escalation study of SGR-1505 as monotherapy in	Schrodinger, 2025- present	Principal investigator for Ion Chiricuta Oncology

		mature B-cell malignancies		
18.	Multiple myeloma	A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients with Multiple Myeloma diagnosed with Secondary Immunodeficiency	Takeda, 2025 - present	Principal investigator for Ion Chircuta Oncology
19.	Primary myelofibrosis, frontline	A frontline, phase 3, randomized, double-blind, add-on study evaluating the safety and efficacy of navtemadlin plus ruxolitinib vs. placebo plus ruxolitinib in myelofibrosis patients who have a suboptimal response to ruxolitinib	Kartos, 2025 - present	Principal investigator for Ion Chircuta Oncology
20.	Follicular lymphoma, frontline	A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and	Abbvie, 2024 - present	Principal investigator for Ion Chircuta Oncology

		<p style="text-align: center;">Lenalidomide (R2) compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORETMFL-2)</p>		
21.	Chronic lymphocytic leukemia, refractory to 2 nd line	<p>A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (GLORA Study)</p>	Ascentage Pharma, 2024 - present	<p>Principal investigator for Ion Chiricuta Oncology</p>
22.	Relapsed/refractory B-cell malignancies	<p>A First-in-Human, Multicenter, Multinational Phase 1a/1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HDP-102 in Patients</p>	Heidelberg Pharma AG, 2024- present	<p>Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca</p>

		with Relapsed/Refractory positive B cell malignancies.		
23	Essential thrombocythemia	ROP-ET: A Phase III, single arm, multicenter study to evaluate the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients who are intolerant or refractory to or not eligible for other cytoreductive treatments	AOP Pharma, 2024 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
24.	Chronic lymphocytic leukemia, 1 st line	A phase 3, randomized study to compare the efficacy and safety of nemtabrutinib versus chemoimmunotherapy for previously untreated chronic lymphocytic leukemia / small lymphocytic lymphoma without TP53 aberrations (Belwave 008)	MSD, 2024 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
25.	Hemophilia A	A multinational, open-label, controlled trial to investigate efficacy	Novo Nordisk, 2024 - present	Principal investigator for Ion

		and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors (FRONTIER-4)		Chiricuta Oncology Institute Cluj Napoca
26.	Chronic lymphocytic leukemia	Phase IV trial to evaluate the results in current clinical practice for patients with chronic lymphocytic leukemia treated with acalabrutinib in Romania (REACH)	Astra Zeneca, 2023 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
27.	Immune thrombocytopenic purpura	Phase 1b study to evaluate the safety and tolerability of multiple subcutaneous administrations of RAY121 in patients with complement- medicated immunological diseases	Chugai Pharmaceuticals, 2024 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
28.	Follicular lymphoma	EpcorReal: A multi- country, prospective observational study of epcoritamab in NHL comprising two patient	Abbive, 2025- present	Principal investigator for Ion Chiricuta Oncology

		cohorts (3L+ [D]LBCL and 3L+ FL)” protocol P24-903		Institute Cluj Napoca
29.	Diffuse large B cell lymphoma	A Randomized, Open-Label, Multicenter, Phase 3 Study of Zilovetamab Vedotin (MK-2140) in Combination With R-CHP Versus R-CHOP in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL) (waveLINE-010)	MSD, 2024 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
30	Chronic lymphocytic leukemia	A phase 2, open label, randomized study evaluating the efficacy and safety of 3 doses of pirtobrutinib in participant with relapsed or refractory chronic lymphocytic leukemia / small lymphocytic lymphoma who previously received treatment with a covalent Bruton	Lilly Pharmaceuticals, 2025 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca

		tyrosine kinase inhibitor		
31.	Multiple myeloma	A prospective multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma	Johnson & Johnson, 2025 - present	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca
32.	Chronic lymphocytic leukemia	A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	Lilly, 2025 - present	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca
33.	Acute myeloid leukemia	A pivotal phase 2/3, multicentric, randomized, double-blind, placebo-controlled, adaptive study design of L-Annamycin for injection in combination with cytarabine injection	Molecullin, 2025 - present	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca

		<p>versus placebo in combination with cytarabine injection as second line therapy for remission induction in adult subjects with refractory/relapsed acute myeloid leukemia (MIRACLE)</p>		
34.	Autoimmune disorders	<p>A Phase 1, Multicenter, Open-label Study of BMS-986515, Healthy Donor Allogeneic CD19- targeted Chimeric Antigen Receptor (CAR) T Cells, in Participants with Severe, Refractory Autoimmune Diseases</p>	<p>Bristol Myers Squibb, 2025 - present</p>	<p>Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca</p>
35.	Chronic lymphocytic leukemia	<p>Prospective Cohort Study With Fixed-Duration Ibrutinib + Venetoclax (I+V) First-Line Treatment in Patients with Chronic Lymphocytic Leukemia in a Real-World</p>	<p>Johnson & Johnson, 2025 - present</p>	<p>Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca</p>

		Setting” (REALITY-RO)		
36.	Myelodysplastic syndromes	A Phase 3, Multicenter, Open Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions	Takeda, 2025 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca
37.	Chronic lymphocytic leukemia	A Study to Investigate Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia	BeOne, 2025 - present	Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca

38.	Chronic lymphocytic leukemia	A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	BeOne, 2025 - present	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca
39.	Autoimmune disorders	Long-term follow-up for subjects treated with gene-modified T cells	Celgene, 2025 - present	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca
40.	Multiple myeloma	A Multicenter, Randomized, Controlled, Open-Label, Group-Sequential, Phase 3 Study to Investigate the Efficacy, Safety and Tolerability of Intravenous Gammagard Liquid (Immune Globulin	Takeda, 2025 - present	Principal investigator for Ion Chircuta Oncology Institute Cluj Napoca

		<p>Infusion, 10%) for Primary Infection Prophylaxis Compared to Secondary Infection Prophylaxis in Adult Patients with Multiple Myeloma receiving B-cell Maturation Antigen (BCMA)-directed Bispecific Antibody Therapy.</p>		
41.	Acute lymphoblastic leukemia	<p>A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL</p>	Amgen, 2025 - present	<p>Principal investigator for Ion Chiricuta Oncology Institute Cluj Napoca</p>

Organizers of Scientific events:

2015, September 11, Cluj Napoca, Romania:

Nanotechnology in leukemia chemotherapy - Congress president.

2016, March 11-12, Cluj Napoca, Romania: Insights in hematology, 1st edition - Congress president

2017, March 10-11, Cluj Napoca, Romania: Insights in hematology, 2nd edition - Congress president

2017, September 9th, Beijing, China: Beijing - Cluj 2017 Hematology Summit Forum

2018, March 9-10, Cluj Napoca, Romania: Insights in hematology, 3rd edition - Congress president

2019, May 12-14, Cluj Napoca, Romania: Insights in hematology, 4th edition - Congress president

2020, September 19th-20th, online edition: Insights in hematology, 5th edition - Congress president

2021, September 19th-20th, hybrid edition: Insights in hematology, 6th edition - Congress president

2022, September 19th-20th, on-site edition: Insights in hematology, 7th edition - Congress president

2023, September 10th-12th, on-site edition: Insights in hematology, 8th edition - Congress president

2024, May 9th-10th, on-site edition: Insights in hematology, 9th edition - Congress president

Initiator and Organizer of the KEYNOTE SPEAKER IN HEMATOLOGY SERIES

- Aaron Ciechanover – Technion Institute of Technology, Haifa, Israel
**Nobel Prize in Chemistry 2004 (December 2018,
September 2022, May 2025)**
- Anders Tveita – University of Oslo, Oslo, Norway (July 2019)
- Hermann Einsele – University of Wurzburg, Wurzburg, Germany (October 2019)
- Erik Aerts – University of Zurich, Zurich, Switzerland (October 2019)
- Gabriel Ghiaur – Johns Hopkins University, Baltimore, MD, USA (November 2019)
- Dieter Hoelzer – University of Frankfurt, Germany (November 2021)
- Masimo Federico – University of Modena, Italy (February 2022)
- Aaron Ciechanover - Technion Institute of Technology, Haifa, Israel (August 2022)
- William Kaelin Jr – Harvard Medical School, Boston, USA (May 2024)
Nobel Prize in Medicine 2019
- Hermann Einsele – University of Wurzburg, Wurzburg, Germany (April 2025)
- Massimo Federico – University of Modena, Italy (September 2025)

Publications:

Books:

1. NANOPHARMACOLOGY IN LEUKEMIA CHEMOTHERAPY. Andrei Cucuianu, **Ciprian Tomuleasa**, Anca Bojan, Cristian Berce, Simion Astilean, Emmet McCormack. Editura Cartea Ardeleana, Cluj Napoca, 2015. ISBN 978-606-8699-74-5.
2. CHIMIOTERAPIE HEMATOLOGICA. **Ciprian Tomuleasa**, Mariana Patiu, Anca Bojan, Mihnea Zdrenghea, Cristian Berce, Ioana Frinc, Bobe Petrushev, Delia Dima, George Calin, Alina Tanase, Stefan Ciurea. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-30-7.
3. HEMATOLOGIA IN IMAGINI. Delia Dima, Mariana Patiu, Anca Bojan, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-69-7.
4. LEUCEMIA MIELOIDA CRONICA. DE LA TERAPIA CU INHIBITORI DE TIROZIN KINAZE LA TRANSPLANT. **Ciprian Tomuleasa**, Delia Dima, Adrian Trifa. Editura Cartea Ardeleana, Cluj Napoca, 2016. ISBN 978-606-8770-98-7.
5. NEOPLASMELE MIELOPROLIFERATIVE. Cristina Bagacean, Iulia Berceanu, Delia Dima, Bogdan Fetica, Jean-Cristophe Ianotto, Mariana Patiu, Adrian Tempescul, **Ciprian Tomuleasa**, Adrian Trifa, Mihnea Zdrenghea. Sub redactia Mihnea Zdrenghea. Editura Casa Cartii de Stiinta, Cluj Napoca, 2017. ISBN 978-606-17-1135-2.
6. GHID DE TRANSPLANT MEDULAR. Alina Tanase, **Ciprian Tomuleasa**. Editura Cartea Ardeleana, ISBN 978-606-797-156-9, Cluj Napoca, 2017.
7. GHIDUL ADULTULUI CU HEMOFILIE. Melen Brinza, Cristina Tarniceriu, Adina Traila, Ciprian Tomuleasa. Editura Medicala. ISBN 978-973-39-0941-5, Bucuresti, 2023

Book chapters:

International:

1. TYPES OF RESEARCH DESIGNS. Fedor Moissenko, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. In "CANCER RESEARCH AND CLINICAL TRIALS IN DEVELOPING COUNTRIES". Springer Science Books, ISBN 978-3-319-18443-2, Cape Town, South Africa 2016.
2. THEORETICAL MODELS OF HEMATOPOIETIC CELL DYNAMICS RELATED TO BONE MARROW TRANSPLANTATION. Radu Precup, Delia Dima, Ciprian Tomuleasa, Marcel Adrian Serban, Lorand Parajdi. In "Frontiers in Stem Cell and Regenerative Medicine Research". Betham Science Publishers, 2017.
3. NON-CODING RNAS IN LUNG CANCER ANGIOGENESIS. Cornelia Braicu, Ciprian Tomuleasa, Diana Gulei, George Adrian Calin, Ioana Berindan-Neagoe. In "Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy", book edited by Dan Simionescu and Agneta Simionescu, ISBN 978-953-51-3024-6, Print ISBN 978-953-51-3023-9, 2017.
4. PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Mihnea Zdrenghea, Delia Dima, **Ciprian Tomuleasa**, Horia Bumbea, Cristina Bagacean. In " New Approaches to the Management of Primary and Secondary CNS Tumors is published " Intech, ISBN 978-953-51-3052-9, 2017.
5. THE USEFULNESS OF BIOMARKERS FOR DIAGNOSIS. Patric Teodorescu, Sergiu Pasca, **Ciprian Tomuleasa**. In "Pineal region lesions. Management strategies and controversial issues. Springer – Zurich, 2020, ISBN 978-3-030-50912-5.

National:

1. CORELATII CLINICO-GENETICO-MOLECULARE IN ONCO-HEMATOLOGIE.

Ciprian Tomuleasa, Delia Dima. In "PROTOCOALE DE DIAGNOSTIC SI TRATAMENT IN HEMATOLOGIE". Andrei Cucuianu. Editura Casa Cartii de Stiinta, Cluj Napoca 2014.

2. ROLUL PROGNOSTIC AL CITOGENETICII SI AL BIOLOGIEI MOLECULARE IN TRANSPLANTUL AUTOLOG DE CELULE STEM HEMATOPOIETICE. **Ciprian Tomuleasa**, Delia Dima, Alina Tanase. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

Ciprian Tomuleasa, Delia Dima, Alina Tanase. In "AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

Orban. Editura Techno Media, Bucharest 2015.

3. REGIMURI DE CONDITIONARE. Alina Tanase, **Ciprian Tomuleasa**. In

"AUTOTRANSPLANTUL DE CELULE STEM HEMATOPOIETICE IN HEMOPATIILE MALIGNNE". Alina Daniela Tanase, Carmen Orban. Editura Techno Media, Bucharest 2015.

4. EVALUAREA CARDIACA PENTRU TRANSPLANTUL DE CELULE STEM

HEMATOPOIETICE. **Ciprian Tomuleasa**, Sergiu Pasca, Anca Bojan, Delia Dima. In "MANUAL DE CARDIOONCOLOGIE". Cristina Vlad, Dan Radulescu, Simona Dragan, Claudia Burz. Editura Medicala Universitara Iuliu Hatieganu 2020.

In extenso publications:

Original Papers in International Scientific Indexed Journals:

1. RECEPTOR TYROSINE KINASES IN CANCER. ONCOGENIC MOLECULAR ALTERATIONS TO THERAPEUTIC HORIZONS IN PRECISION MEDICINE.

Ciprian Tomuleasa, Adrian-Bogdan Tigu, Raluca Munteanu, Cristian-Silviu Moldovan, David Kegyes, Anca Onaciu, Diana Gulei, Gabriel Ghiaur, Hermann Einsele, Carlo M. Croce. Signal Transduction and Targeted Therapy 2024, **impact factor: 52.7**, in press.

2. HORIZON 2020. FUNDS TO HELP EASTERN EUROPE CLOSE THE GAP. Cristian Berce, **Ciprian Tomuleasa**, Radu Meza. Nature 2017, 541(7636):157-157. **impact factor: 38.138.**
3. PATIENT SELECTION FOR CAR-T OR BITE THERAPY IN MULTIPLE MYELOMA. WHICH TREATMENT FOR EACH PATIENT? David Kegyes, Catalin Constantinescu, Louise Vrancken, Leo Rasche, Celine Gregoire, Bogdan Tigu, Delia Dima, Diana Gulei, Alina Tanase, Hermann Einsele, Stefan Ciurea, **Ciprian Tomuleasa**, Jo Caers. Journal of Hematology and Oncology 2022, **impact factor: 23.168**, in press.
4. INSIGHTS INTO THE ROLES OF UBIQUITIN LIGASE KPC1: FROM CELL CYCLE CONTROL TO NF-KB REGULATOR. Diana Gulei, Rares Drula, Gabriel Ghiaur, Anca Dana Buzoianu, **Ciprian Tomuleasa**, Aaron Ciechanover. Cancer Research, 2023, in press. **impact factor: 13.312.**
5. CONTINUOUS RENAL REPLACEMENT THERAPY IN CYTOKINE RELEASE SYNDROME FOLLOWING IMMUNOTHERAPY OR CELLULAR THERAPIES? Catalin Constantinescu, Sergiu Pasca, Tiberiu Tat, Patric Teodorescu, Catalin Vlad, Sabina Iluta, Dana Tomescu, Delia Dima, Ecaterina Scarlatescu, Alina Tanase, Anca Colita, Olafur Eysteinn Sigurjonsson, Hermann Einsele, **Ciprian Tomuleasa**. Journal of Immunotherapy of Cancer, 2020, in press. **impact factor: 12.469.**
6. DESIGN AND IMPLEMENTATION OF A HUMANITARIAN CANCER PROGRAM FOR UKRAINIAN REFUGEES IN MOLDOVA AND ROMANIA. Horia Vulpe, et al, **Ciprian Tomuleasa**, Gabriel Ricu, Rodica Mindruta-Stratan, Catalin Danaila, Dragos Iancu, Ludmila Circiumari, Cristian Teglas, Lars Lonback, Violina Nazaria, Ursula Wagner, Eugenia Ciubotaru, Nicoleta Minzatean, Ciprian Jitaru, Sanislav Polozov, Inessa Matiushenko, Anna Uzlova, Richard Sullivan, Stefania Magidson. Lancet Oncology, 2023, in press. **impact factor: 51.1.**
7. THE INTERPLAY BETWEEN CANCER CELLS, MACROPHAGES AND NATURAL KILLER CELLS MAY ACTUALLY DECIDE THE OUTCOME OF THERAPY WITH SORAFENIB. **Tomuleasa C**, Giannelli G, Cucuianu A, Aldea M, Paradiso A, Berindan-Neagoe I. Hepatology. 2014; 60(1):430. **impact factor: 12.008.**
8. HUMAN BILE CONTAIN MICRORNA-LADEN EXOSOMES THAT CAN BE USED FOR CHOLANGIOCARCINOMA DIAGOSIS. Ling Li, David Masica, Masaharu Ishida,

Ciprian Tomuleasa, Sho Umegaki, Anthony N. Kalloo, Christos Georgiades, Vikesh K. Singh, Mouen Khashab, Stuart Amateau, Zhiping Li, Patrick Okolo, Anne-Marie Lennon, Payal Saxena, Jean-Francois Geschwind, Todd Schlachter, Kelvin Hong, Timothy M. Pawlik, Marcia Canto, Joanna Law, Reem Sharaiha, Clifford R. Weiss, Haoran Peng, Paul Thuluvath, Michael Goggins, Eun Ji Shin, Vivek Kumbhari, Susan Hutfless, Liya Zhou, Esteban Mezey, Stephen J. Meltzer, Rachel Karchin, Florin M. Selaru. *Hepatology*. 2014;60(3):896-907. **impact factor: 12.008**.

9. TARGETING DEGRADATION OF IKZF1 AND IKZF3 THROUGH MODULATION OF THE E3 LIGASE SUBSTRATES IN THE CONTEXT OF CELLULAT THERAPIES FOR MULTIPLE MYELOMA. David Kegyes, Anamaria Bancos, Adrian Bogdan Tigu, Ioana Rus, Delia Dima, Diana Cenariu, Madalina Nistor, Diana Gulei, Alina Tanase, Anca Colita, Anca Buzoianu, Cristina Iuga, Mihnea Zdrenghea, Evangelos Terpos, Stefan O. Ciurea, Aaron Ciechanover, Hermann Einsele, **Ciprian Tomuleasa**. *Biomarker Research* 2025, **impact factor: 11.5**, in press.
10. ADVANCES IN MEASURABLE RESIDUAL DISEASE ASSESSMENT FOR ACUTE MYELOID LEUKEMIA: FROM CYTOGENETICS AND MOLECULAR BIOLOGY TO ASSESSMENT OF THE METHYLATION PATTERN AND SERS AS EMERGING TECHNOLOGIES. Anamaria Bancos, Andrei Ivancuta, Vlad Moisoiu, Diana Gulei, Adrian-Bogdan Tigu, Madalina Nistor, Cristian Silviu Moldovan, David Kegyes, Diana Cenariu, Mihnea Zdrenghea, Anca Bojan, Alina Tanase, Stefania D. Iancu, Nicolae Leopold, Horia Bumbea, Gabriel Ghiaur, Hermann Einsele, Stefan O. Ciurea, **Ciprian Tomuleasa**. *Biomarker Research* 2025, **impact factor: 11.5**, in press.
11. CANCER-ASSOCIATED RS6983267 SNP AND ITS ACOMPANYING RNA CCAT2 INDUCE MYELOID MALIGNANCIES VIA UNIQUE SNP-SPECIFIC RNA MUTATIONS. Maitri Shah, Valentina Pileczki, Linda Fabris, Manuela Ferracin, Roxana Redis, Maria Ciccone, Xinna Zhang, Masayoshi Shimizu, Cristian Rodriguez-Aguayo, Maria Angelica Cortez, Cristina Ivan, Taghi Manshour, Steliana Calin, Jan Parker-Thornburg, Asha Multani, James Welsh, Marcos Estecio, Hui Ling, **Ciprian Tomuleasa**, Delia Dima, Hui Yang, M. James You, Srdan Verstovsek, Milan Radovich, Katy Rezvani, Elizabeth Shpall, Leonard Girnita, Ioana Berindan-Neagoe, Riccardo Fodde, Carlos

Bueso-Ramos, Mihai Gagea, Guillermo Garcia-Manero, Ines Almeida, Daniela Nedelcu, Muharrem Muftuoglu, Pinaki Banerjee, Mustafa Badiwi, George Calin. *Genome Research* 2017, **impact factor: 11.351**.

12. UNEXPLAINED HEMORRHAGIC SYNDROME? CONSIDER ACQUIRED HEMOPHILIA A OR B. Catalin Constantinescu, Ciprian Jitaru, Sergiu Pasca, Delia Dima, Noemi Dirzu, Daniel Coriu, Joanna Zdziarska, Gabriel Ghiaur, Johny Mahlangu, **Ciprian Tomuleasa**. *Blood Reviews*, 2021, in press. **impact factor: 10.626**.
13. EXPLOITING THE UBIQUITIN SYSTEM IN MYELOID MALIGNANCIES. FROM BASIC RESEARCH TO DRUG DISCOVERY IN MDS AND AML. Rares Drula, Sabina Iluta, Diana Gulei, Delia Dima, Cristina Iuga, Anca Dana Buzoianu, Gabriel Ghiaur, Aaron Ciechanover, **Ciprian Tomuleasa**. *Blood Reviews*, 2022, in press. **impact factor: 10.626**.
14. SWITCHING FROM SALVAGE CHEMOTHERAPY TO IMMUNOTHERAPY IN ADULT B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. David Kegyes, Ciprian Jitaru, Gabriel Ghiaur, Stefan Ciurea, Dieter Hoelzer, **Ciprian Tomuleasa**, Robert Peter Gale. *Blood Reviews*, 2023, **impact factor: 10.626**. in press.
15. PROTEASOME INHIBITION IN COMBINATION WITH IMMUNOTHERAPIES: STATE-OF-THE-ART IN MULTIPLE MYELOMA. David Kegyes, Diana Gulei, Rares Drula, Diana Cenariu, Bogdan Tigiu, Delia Dima, Alina Tanase, Sorina Badelita, Anca-Dana Buzoianu, Stefan Ciurea, Gabriel Ghiaur, Evangelos Terpos, Aaron Ciechanover, Hermann Einsele, **Ciprian Tomuleasa**. *Blood Reviews*, 2023, in press, **impact factor: 10.636**.
16. DIVINE MESSENGERS: ARE EXOSOMES THE HERMESES OF MODERN MOLECULAR ONCOLOGY? **Ciprian Tomuleasa**, Cornelia Braicu, Pamela Monroig, Andrei Cucuianu, Ioana Berindan-Neagoe, George A. Calin. *Cell Death Differentiation*. 2015; 22(1):34-45. **impact factor: 8.371**.
17. NANOMEDICINE FOR ACUTE LYMPHOBLASTIC LEUKEMIA DETECTION AND TREATMENT. Andra Sorina Tatar, Timea Simon, Simion Astilean, **Ciprian Tomuleasa**, Sanda Boca. *Journal of Controlled Release*, 2016; 238:123-38. **impact factor: 8.407**.
18. HUMANIZED MOUSE MODELS IN MDS. Raluca Munteanu, Diana Gulei, Cristian-Silviu Moldovan, Emanuele Azzoni, Laura Belver, Richard Feder, Simina Pirv, Anca Dana

Buzoianu, Hermann Einsele, Moshe Mittelman, Gabriel Ghiaur, Robert Hasserjian, **Ciprian Tomuleasa**. Cell Death Disease 2025, **impact factor : 8.1**. in press.

19. REAL WORLD TREATMENT PATTERNS AND HEALTHCARE RESOURCE USE IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE METER STUDY. Vikas Gupta, **Ciprian Tomuleasa**, Gilberto Israel Barranco Lampon, Hsin-An Hou, Grzegorz Helbig, Pankit Vachhani, Argiris Symeonidis, Ibrahim Haznedaroglu, Kenny Galvez, Fernando Tatsch, Avijeet S Chopra, Meng Zhang, Tamas Vizkelety, Bryan Murray, David M Ross. Blood Advances 2024, submitted for publication. **impact factor: 7.6**.
20. UNLOCKING PROTEIN-BASED BIOMARKER POTENTIAL FOR GRAFT VERSUS HOST DISEASE FOLLOWING HEMATOPOIETIC STEM CELL TRANSPLANTS. Maria Iacobescu, Cristina Pop, Alina Uifălean, Cristina Ionela Mogoșan, Diana Cenariu, Mihnea Zdrenghea, Alina Daniela Tănase, Jon Thor Bergthorsson, Victor Greiff, Mihai Cenariu, Cristina Adela Iuga, **Ciprian Tomuleasa**. Dan Tătaru. Frontiers in Immunology 2024, in press. **impact factor: 7.3**.
21. ANTIBODY CONJUGATED, RAMAN-TAGGED HOLLOW GOLD NANOSPHERES FOR SPECIFIC TARGETING AND MULTIMODAL DF/SERS/TPE-FLIM IMAGING OF CD19(+) B LYMPHOBLASTS. Timea Nagy-Simon, Andra-Sorina Tatar, Ana-Maria Craciun, Adriana Vulpoi, Maria-Ancuta Jurj, Adrian Florea, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Simion Astilean, Sanda Boca. ACS Applied Materials & Interfaces, in press. **impact factor: 7.145**.
22. THE ROLE OF MICRORNAS IN THE PATHOGENESIS OF HIV-RELATED LYMPHOMAS. Ravnit Grewal, Andrei Cucuianu, Carmen Swanepoel, Delia Dima, Bobe Petrushev, Bogdan Pop, Ioana Berindan-Neagoe, Emmanuel Akin Abayomi, **Ciprian Tomuleasa**. Critical Reviews in Clinical Laboratory Sciences 2015, 52(5):232-41. **impact factor: 7.00**.
23. NEURO-TOXICITIES OF CHEMO- AND IMMUNE-THERAPIES IN HAEMATOLOGICAL MALIGNANCIES : FROM MECHANISM TO MANAGEMENT. David Kegyey, Vlad Moisoiu, Catalin Constantinescu, Alina Tanase, Gabriel Ghiaur, Hermann Einsele, **Ciprian Tomuleasa**, Hillard Lazarus, Robert Peter Gale. Blood Reviews 2024, in press. **impact factor: 6.9**.

24. PITFALLS IN PATENTING ACADEMIC CAR-T CELLS THERAPY. Catalin Constantinescu, Roxana Constantinescu, Jon Thor Bergthorsson, Victor Greiff, Alina Tanase, Anca Colita, Diana Gulei, **Ciprian Tomuleasa**. Expert Opinion on Therapeutic Patents, 2023, impact factor: 6.714, in press.
25. PSEUDOGENE INTS6P1 REGULATES IT'S CONGNATE GENE INTS6 THROUGH COMPETITIVE BINDING OF MIR-17-5P IN HEPATOCELLULAR CARCINOMA. Haoran Peng, Masaharu Ishida, Atsushi Saito, Atsushi Kamiya, James P. Hamilton, Rongdang Fu, Alexandru V. Oлару, Fangmei An, Irinel Popescu, Razvan Iacob, Simona Dima, Sorin T. Alexandrescu, Razvan Grigorie, Anca Nastase, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Florin Graur, Florin Zaharia, Michael S. Torbenson, Esteban Mezey, Minqiang Lu, Florin M. Selaru. Oncotarget 2015; ;6(8):5666-77. **impact factor: 6.63**.
26. TRANSIENT LEUKEMIA OF DOWN SYNDROME. Sas Valentina, Blag Cristina, Zaharie Gabriela, Andronic-Gorcea Nicolae, Pasca Sergiu, Petrushev Bobe, Chis Irina, Marian Mirela, Dima Delia, Zdrenghia Mihnea, Berindan-Neagoe Ioana, Popa Gheorghe, Man Sorin, Colita Anca, Stefan Cristina, Kojima Seiji, **Tomuleasa Ciprian**. Critical Reviews in Clinical Laboratory Sciences, 2019, in press. **impact factor: 6.481**.
27. THE NF-KB P50 SUBUNIT GENERATED BY KPC1-MEDIATED UBIQUITINATION AND LIMITED PROTEASOMAL PROCESSING, SUPPRESSES TUMOR GROWTH. Yelena Kravtsova-Ivantsiv, Gilad Goldhirsh, Ciprian Tomuleasa, Eli Pikarsky, Aaron Ciechanover. Cancer Cell International 2023, in press. impact factor: 6.436.
28. MICRORNAS ASSOCIATED WITH A GOOD PROGNOSIS OF ACUTE MYELOID LEUKEMIA AND THEIR EFFECT ON MACROPHAGE POLARIZATION. Alexandra Neaga, Cristina Bagacean, Adrian Tempescul, Laura Jimbu, Oana Mesaros, Cristina Lucia Blag, **Ciprian Tomuleasa**, Corina Bocsan, Mihaela Gaman, Mihnea Zdrenghia. Frontiers in Immunology, 2020, in press, **impact factor: 6.429**.
29. IMMUNE THERAPIES OF B-CELL ACUTE LYMPHOBLASTIC LEUKAEMIA IN CHILDREN AND ADULTS. David Kegyes, Gabriel Ghiaur, Anamaria Bancos, **Ciprian Tomuleasa**, Robert Peter Gale. Critical Reviews in Oncology / Hematology, 2024, in press. **impact factor: 6.2**.

30. COMPREHENSIVE VIEW ON CHEMOTHERAPY-FREE MANAGEMENT OF ACUTE MYELOID LEUKEMIA BY USING VENETOCLAX IN COMBINATION WITH TARGETED AND/OR IMMUNE THERAPIES. David Kegyes, Andrei Tat, Alin Stefan Vizitiu, Daiana Vazar-Tripon, Radu Ilie, Adrian Bogdan Tigiu, Diana Cenariu, Anamaria Bancos, Sabina Iluta, Ciprian Jitaru, Madalina Nistor, Radu Tomai, Hermann Einsele, Gabriel Ghiaur, Carlo M. Croce, **Ciprian Tomuleasa**. Cell Death Discovery 2025, in press. **impact factor: 6.1**.
31. A COMPREHENSIVE PICTURE OF EXTRACELLULAR VESICLES AND THEIR CONTENT. Ancuta Jurj, Oana Zanoaga, Cornelia Braicu, Vladimir Lazar, **Ciprian Tomuleasa**, Alexandru Irimie, Ioana Berindan-Neagoe. Cancers, 2020, in press. **impact factor: 6.102**.
32. THERAPEUTIC ADVANTAGES IN THE TARGETING OF ROR1 IN HEMATOLOGICAL CANCERS. Adrian Bogdan Tigiu, **Ciprian Tomuleasa**, Raluca Munteanu, Cristian Moldovan, Rareş Drula, Radu Tomai, David Kegyes, Vlad Moisoiu, Gabriel Ghiaur, Diana Gulei, Hermann Einsele, Carlo M. Croce. Cell Death Discovery 2024, **impact factor: 6.1**, in press.
33. CHARACTERISTICS OF DENTAL RESIN BASED COMPOSITES IN LEUKEMIA SALIVA: AN IN VITRO ANALYSIS. Alexandru Mester, Marioara Moldovan, Stanca Cuc, **Ciprian Tomuleasa**, Sergiu Pasca, Miuta Filip, Andra Piciu, Florin Onisor. Biomedicines 2021, in press. **impact factor: 6.081**.
34. MIR-543 REGULATES THE EPIGENETIC LANDSCAPE OF MYELOFIBROSIS BY TARGETTING TET1 AND TET2. Enrique Fuentes-Mattei , Recep Bayraktar, Taghi Manshour, Andreia Silva, Cristina Ivan, Diana Gulei, Linda Fabris, Nayra Soares, Pilar Mur, Cristina Perez-Caro, Elizabeth Torres-Claudio, Mihnea Dragomir, Adriana Grisselle Badillo, Erik Knutsen, Pranav Narayanan, Leonard Golfman, Masayoshi Shimizu, Xinna Zhang, Wanke Zhao, Wanting Ho, Marcos R. H. Estecio, Geoffrey Bartholomeusz, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Patrick Zweidler-McKay, Zeev Estrov, Joe Zhao, Srdan Verstovsek, George A. Calin, Roxana Redis. Journal of Clinical Investigation Insights, 2020, in press, **impact factor: 6.014**.
35. PATTERNS OF HEALTHCARE RESOURCE UTILIZATION (HRU) IN UNFIT PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) RECEIVING FIRST LINE

- SYSTEMIC TREATMENT OR BEST SUPPORTIVE CASE (BSC): A MULTICENTER INTERNATIONAL STUDY (CURRENT). T Ito, D Sanford, **C Tomuleasa**, HH Hsiao, LJ Enciso Oliveira, AK Enjeti, Conca A Gimenez, T Barnal del Castillo, L Girsova, MP Martelli, B Guvenc, CN Bui, A Delgado, Y Duan, B Garbavo Guijarro, C Llamas, JH Lee. Value in Health, 2021, in press, **impact factor: 6.**
36. PROTEOLYSIS TARGETING CHIMERIC-BASED TECHNOLOGY IN MYELOMA AND LYMPHOMA. Adrian-Bogdan Tigu, Andrei Ivancuta, **Ciprian Tomuleasa**, Madalina Nistor, David Kegyes, Diana Cenariu, Raluca Munteanu, Anca-Dana Buzoianu, Hermann Einsele, Massimo Federico, Sebastian Kobold, Diana Gulei, Aaron Ciechanover. Molecular Cancer Therapeutics 2025, in press. **impact factor: 5.9.**
37. SERS-BASED EVALUATION OF METHYLATION PROGRESSION IN CLONAL LEUKEMOGENESIS OF DOWN SYNDROME. Vlad Moisoiu, Valentina Sas, Andrei Stefanu, Stefania D. Iancu, Ancuta Jurj, Sergiu Pasca, Sabina Iluta, Alina-Andreea Zimta, Adrian B. Tigu, Delia Dima, Patric Teodorescu, Cristina Turcas, Cristina Blag, Delia Dima, Gheorghe Popa, Smaranda Arghirescu, Sorin Man, Anca Colita, Nicolae Leopold, **Ciprian Tomuleasa**. Frontiers in Bioengineering and Biotechnology, 2021, in press, **impact factor: 5.89.**
38. NOVEL INSIGHTS INTO TRIPLE-NEGATIVE BREAST CANCERS, THE EMERGING ROLE OF ANGIOGENESIS, AND ANTIANGIOGENIC THERAPY. Cornelia Braicu, Roxana Chiorean, Alexandru Irimie, Sergiu Chira, **Ciprian Tomuleasa**, Emilian Neagoe, Angelo Paradiso, Patriciu Achimas-Cadariu, Vladimir Lazar, Ioana Berindan-Neagoe. Expert Reviews in Molecular Medicine. 2016; 18:e18. **impact factor: 5.71.**
39. CHIMERIC ANTIGEN RECEPTOR T CELLS FOR THE TREATMENT OF B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. **Ciprian Tomuleasa**, Shigeo Fuji, Cristian Berce, Anca Onaciu, Sergiu Chira, Bobe Petrushev, Wilhelm Thomas Micu, Vlad Moisoiu, Sergiu Pasca, Ciprian Osan, Catalin Constantinescu, Ancuta Jurj, Laura Pop, Ioana Berindan-Neagoe, Delia Dima, Shigehisa Kitano. Frontiers in Immunology, in press. **impact factor: 6.429.**

40. THE POTENTIAL EQUIVALENTS OF TET2 MUTATIONS. Sergiu Pasca, Ancuta Jurj, Mihnea Zdrenghea, **Ciprian Tomuleasa**. *Cancers*, 2021, in press. **impact factor: 6.126**.
41. EFFECTS OF LEUKEMIA SALIVA ON DENTAL RESIN-BASED COMPOSITES: AN IN VITRO ANALYSIS. Alexandru Mester, Marioara Moldovan, Stanca Cuc, **Ciprian Tomuleasa**, Sergiu Pasca, Miuta Filip, Andra Piciu, Florin Onisor. *Biomedicines*, 2021, in press. **impact factor: 6.081**.
42. THE THERAPEUTIC MANIPULATION OF IL-10 AND PROGRAMMED DEATH LIGAND-1 IN ACUTE MYELOID LEUKAEMIA: THE ADVANTAGE OF TARGETING BOTH PD-L1/PD-L2-PD-1 AND IL-10-IL-10R PATHWAYS. Laura Jimbu, Oana Mesaros, Alexandra Neaga, Ana Maria Nanut, **Ciprian Tomuleasa**, Delia Dima, Corina Bocsan, Mihnea Zdrenghea. *Pharmaceuticals*, 2021, in press. **impact factor: 5.863**.
43. LOOKING AHEAD ON TARGETING MACROPHAGES BY CAR T- OR NK-CELLS. David Kegyes, Paul Alexandru Milea, Andreea-Isabella Mazga, Adrian-Bogdan Ţigu, Madalina Nistor, Diana Cenariu, Radu Tomai, Sanda Buruiana, Hermann Einsele, Alina Daniela Tănase, **Ciprian Tomuleasa**. *Expert Opinion of Therapeutic Targets 2024*, in press. **impact factor: 5.8**.
44. CHALLENGES IN THE PRECLINICAL DESIGN AND ASSESSMENT OF CAR T CELLS. Radu Tomai, Javier De Las Rivas, Bogdan Fetica, Rui Bergatim, Brankica Filipic, Zarko Gagic, Katarina Nikolic, Diana Gulei, David Kegyes, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Richard Feder, Mariana Pavel-Tanase, Andrei Cianga, Adrian Bogdan Tigu, Raluca Munteanu, Alina Tanase, Hermann Einsele, **Ciprian Tomuleasa**. *Frontiers in Immunology 2025*, in press, **impact factor : 5.7**.
45. CARING ABOUT AUTOIMUNE DISORDERS. USE OF CHIMERIC ANTIGEN RECEPTOR ENGINEERED T-CELLS IN AUTOIMMUNE DISEASES. Adrian-Bogdan Tigu, Madalina Nistor, Diana Gulei, David Kegyes, Diana Cenariu, Ximena Muresan, Raluca Munteanu, Richard Feder, Ciprian Jitaru, Anamaria Bancos, Maria Santa, Radu Tomai, Marc Damian, Andrei Ivancuta, Mihnea Zdrenghea, Anca-Dana Buzoianu, Alina Tanase, Hermann Einsele, Sebastian Kobold, **Ciprian Tomuleasa**. *Blood Reviews 2025*, in press. **impact factor: 5.7**.

46. APPROACH TO THE ACUTE LYMPHOBLASTIC LEUKEMIA PATIENT. Valentina Sas, Vlad Moisoiu, Patric Teodorescu, Sebastian Tranca, Laura Pop, Sabina Iluta, Sergiu Pasca, Cristina Blag, Sorin Man, Andrei Roman, Catalin Constantinescu, Ioana Rus, Mihail Buse, Cosmin Lisencu, Bogdan Fetica, Mirela Marian, Cristina Selicean, Ioana Berindan-Neagoe, Bobe Petrushev, Horia Bumbea, Alina Tanase, Mihnea Zdrenghea, Shigeo Fuji, Shigehisa Kitano, **Ciprian Tomuleasa**, Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation. Journal of Clinical Medicine, 2019, in press. **impact factor: 5.688.**
47. DIFFERENTIAL DIAGNOSIS OF MALIGNANT LYMPHADENOPATHY USING FLOW CYTOMETRY ON FINE NEEDLE ASPIRATION. REPORT ON 269 CASES. Carla Griesel, Minodora Desmirean, Tonya Esterhuizen, Sergiu Pasca, Bobe Petrushev, Cristina Selicean, Andrei Roman, Bogdan Fetica, Carmen Swanepoel, **Ciprian Tomuleasa**, Ravnit Grewal. Journal of Clinical Medicine, 2020, in press, **impact factor: 5.688.**
48. IN VIVO IMAGING SYSTEM (IVIS) THERAPEUTIC ASSESSMENT OF TYROSINE KINASE INHIBITOR LOADED GOLD ANOCARRIERS FOR ACUTE MYELOID LEUKEMIA. Raluca-Andrada Munteanu, Adrian Bogdan Tigu, Richard Feder, Andra-Sorina Tatar, Diana Gulei, **Ciprian Tomuleasa**, Sanda Boca. Frontiers in Pharmacology 2024, impact factor: 5.6, in press
49. MICRORNA-155-5P PLAYS A CRITICAL ROLE IN TRANSIENT LEUKEMIA OF DOWN SYNDROME BY TARGETING TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBERS. Valentina Sas, Sergiu Sas, Ancuta Jurj, Laura Pop, Liviuta Budisan, Hideki Muramatsu, Delia Dima, Patric Teodorescu, Sabina Iluta, Cristina Turcas, Anca Onaciu, Raluca Munteanu, Diana Gulei, Alina-Andreea Zimta, Alexander von Gamm, Cristina Blag, Gheorghe Popa, Smaranda Arghirescu, Margit Serban, Sorin Man, Mirela Marian, Cristian Berce, Anca Colita, Alina Tanase, Mihnea Zdrenghea, Seiji Kojima, Diana Gulei, Yoshiyuki Takahashi, **Ciprian Tomuleasa**. Cellular Physiology and Biochemistry, 2020, in press. **impact factor: 5.5.**
50. UNDERSTANDING DNA EPIGENETICS BY MEANS OF RAMAN/SERS ANALYSIS FOR CANCER DETECTION APPLICATIONS. Luca David, Anca Onaciu, Valentin Toma, Rareş-Mario Borşa, Cristian Moldovan, Adrian-Bogdan Țigu, Diana

Cenariu, Ioan Simon, Gabriela-Fabiola Știufiuc, Eugen Carasevici, Brindusa Dragoi, **Ciprian Tomuleasa**, Rareș-Ionuț Știufiuc. Biosensors 2024, in press. **impact factor: 5.4.**

51. HODGKIN'S LYMPHOMA AND ITS ASSOCIATION WITH EBV AND HIV INFECTION. Grewal Ravnit, Alexandra Irimie, Naidoo Nasheen, Mohamed Nooroudien, Petrushev Bobe, Chetty Manogari, **Tomuleasa Ciprian**, Abayomi Emmanuel Akinola. Critical Reviews in Clinical Laboratory Sciences, in press. **impact factor: 5.340.**
52. A HYPOTHESIS OF TREATMENT STRATEGY OF SEVERE MULTICENTRIC CASTLEMAN'S DISEASE WITH CONTINUOUS RENAL REPLACEMENT THERAPY. Catalin Constantinescu, David Kegyes, Vlad Moisoiu, Olga Grajdieru, Andrea Szekely, Evangelos Terpos, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine 2024, in press. **impact factor: 5.31.**
53. SINGLE, LOW DOSE DECITABINE AS FRONTLINE THERAPY OF ACUTE MYELOID LEUKEMIA, WITH VENETOCLAX SALVAGE. Ciprian Jitaru, Mareike Peters, Lovisha Aggarwal, Anamaria Bancos, Adrian Tigu, Diana Cenariu, Cristina Selicean, Sergiu Pasca, Vlad Moisoiu, Petra Rotariu, Maria Santa, Sabina Iluta, Rareș Drula, David Kegyes, Aranka Kurtus, Mihnea Zdrenghea, Lukasz Gondek, **Ciprian Tomuleasa**, Gabriel Ghiaur. Journal of Cellular and Molecular Medicine 2024, in press. **impact factor: 5.31.**
54. RNA METHYLATION SEQUENCING SHOWS DIFFERENT GENE EXPRESSION SIGNATURES FOR RESPONSE TO AZACYTIDINE THERAPY IN HIGH-GRADE MYELODYSPLASTIC SYNDROMES. Diana Gulei, Vlad Moisoiu, David Kegyes, Rares Drula, Sabina Iluta, Adrian Bogdan Tigu, Madalina Nistor, Ciprian Jitaru, Anamaria Bancos, Petra Rotariu, Corina Popovici, Delia Dima, Radu Tomai, Ioana Rus, Catalin Constantinescu, Raluca Munteanu, Diana Cenariu, Ugur Sezerman, Mihnea Zdrenghea, Jaroslav Cermak, Hermann Einsele, Gabriel Ghiaur, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine 2024, **impact factor: 5.259**, in press.
55. MAGNETIC RESONANCE IMAGING-BASED DIAGNOSIS OF PROGRESIVE MULTIFOCAL LEUKOENCEPHALOPATHY IN A PATIENT WITH NON-HODGKIN'S LYMPHOMA FOLLOWING THERAPY WITH CYCLOPHOSPHAMIDE, HYDROXYDAUNORUBICIN, VINCRISTINE,

- PREDNISONE AND RITUXIMAB. Delia Dima, **Ciprian Tomuleasa**, Alexandru Irimie, Ioan Stefan Florian, Bobe Petrushev, Ioana Berindan-Neagoe, Andrei Cucuianu. *Cancer*. 2014;120(24):4005-6. **impact factor: 5.2**.
56. RNA SEQUENCING SUGGESTS THAT NON-CODING RNAs PLAY A ROLE IN THE DEVELOPMENT OF ACQUIRED HEMOPHILIA. Bogdan Tigu, Ionut Hotea, Cristina Blag, Rares Drula, Alina-Andreea Zimta, Noemi Dirzu, Maria Santa, Delia Dima, Jon Thor Bergthorsson, Victor Greiff, Margit Serban, Daniel Coriu, Diana Gulei, Johnny Mahlangu, **Ciprian Tomuleasa**. *Journal of Cellular and Molecular Medicine*, 2023, in press. **impact factor: 5.295**.
57. DESIGN AND PRECLINICAL TESTING OF AN ANTI-CD41 CAR T CELL FOR THE TREATMENT OF ACUTE MEGAKARYOBLASTIC LEUKEMIA. Adrian-Bogdan Tigu, Catalin Constantinescu, Patric Teodorescu, David Kegyes, Richard Feder, Mareike Peters, Ioana Pralea, Cristina Iuga, Diana Cenariu, Andra Marcu, Alina Tanase, Anca Colita, Rares Drula, Jon Thor Bergthorsson, Victor Greiff, Delia Dima, Ioana Rus, Mihnea Zdrengea, Diana Gulei, Gabriel Ghiaur, **Ciprian Tomuleasa**. *Journal of Cellular and Molecular Medicine*, 2023, in press. **impact factor: 5.295**.
58. CLINICAL APPROACH TO THE PATIENT IN CRITICAL CONDITION FOLLOWING IMMUNOTHERAPY AND/OR STEM CELL TRANSPLANTATION. GUIDELINE FOR THE ON-CALL PHYSICIAN. Catalin Constantinescu, Constantin Bodolea, Sergiu Pasca, Delia Dima, Ioana Rus, Tiberiu Tat, Patric Teodorescu, Patriciu Achimas-Cadariu, Alina Tanase, **Ciprian Tomuleasa**, Hermann Einsele. *Journal of Clinical Medicine*, 2019, in press. **impact factor: 5.306**.
59. SERS-BASED ASSESSMENT OF DNA METHYLATION FOR THE EVALUATION OF MRD IN ACUTE PROMYELOCYTIC LEUKEMIA. Anamaria Bancos, Stefania D. Iancu, Vlad Moisoiu, Alexandra Ghiaur, Adrian Bogdan Tigu, Cristina Buran, Georgiana Ion, Camelia Stancioaca, Bogdan Ionescu, Mihaela Dragomir, Codruta F. Buldus, Diana Cenariu, Madalina Nistor, Diana Gulei, David Kegyes, Nicolae Leopold, Daniel Coriu, **Ciprian Tomuleasa**. *Journal of Cellular and Molecular Medicine* 2024, **impact factor: 5.259**, in press.
60. MECOM, HBS1L-MYB, THRB-RARB, JAK2 and TERT polymorphisms defining predisposition to myeloproliferative neoplasms - a study on 939 patients. Adrian Trifa,

Claudia Banescu, Anca Bojan, Alina Popa, Florin Tripon, Delia Dima, Viola Maria Popov, Stefan Vesa, Mihaela Andreescu, Tunde Torok-Vistai, Romeo Mihaila, Nicoleta Berbec, Ion Macarie, Andrei Colita, Maria Iordache, Alina Catana, Marius Farcas, **Ciprian Tomuleasa**, Kinga Vasile, Cristina Truica, Adriana Todinca, Lavinia Muntean, Raluca Manolache, Horia Bumbea, Ana-Maria Vladareanu, Mihaela Dervesteanu, Cristina Ciufu, Radu Popp. American Journal of Hematology 2017, in press. **impact factor: 5.275.**

61. SERS LIQUID BIOPSY: AN EMERGING TOOL FOR MEDICAL DIAGNOSIS. Vlad Moisoiu, Stefania Dana Iancu, Andrei Stefancu, Tudor Moisoiu, Barbara Pardini, Mihnea Paul Dragomir, Nicolae Crisan, Lucretia Avram, Dana Crisan, Iulia Andras, Daniela Fodor, Carmen Socaciu, Zoltán Bálint, **Ciprian Tomuleasa**, Nicolae Leopold, Florin Elec. Colloids and Surfaces B: Biointerfaces, 2021, in press. **impact factor: 5.268.**
62. HEMATOPOIETIC STEM CELL TRANSPLANTATION IN ACUTE PROMYELOCYTIC LEUKEMIA IN THE ATRA/ATO ERA. Andrei Colita, Alina Daniela Tanase, **Ciprian Tomuleasa**, Anca Colita. Cancers 2023, **impact factor: 5.2**, in press.
63. EXPLORING THERAPEUTIC AVENUES IN LUNG CANCER: THE EPIGENETIC PERSPECTIVE. Raluca Munteanu, **Ciprian Tomuleasa**, Cristina Adela Iuga, Diana Gulei, Tudor Eliade Ciuleanu. Cancers 2023, in press. **impact factor: 5.2.**
64. MOLECULAR SUBTYPES AND THE ROLE OF TP53 IN DIFFUSE LARGE B-CELL LYMPHOMA AND RICHTER SYNDROME. Ivan Negara, **Ciprian Tomuleasa**, Sanda Buruiana, Dimitar G. Efremov. Cancers 2024, **impact factor: 5.2**, in press
65. ASSESSING MEASURABLE RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA. BCR-ABL IS IN THE *AVANT-GARDE* OF MOLECULAR HEMATOLOGY. Vlad Moisoiu, Delia Dima, Lorand Parajdi, Sergiu Pasca, Patric Teodorescu, Radu Precup, **Ciprian Tomuleasa**, Simona Soverini. Frontiers in Oncology, 2019, in press, **impact factor: 5.165.**
66. LET'S TALK ABOUT BITES AND OTHER DRUGS IN THE REAL LIFE SETTING FOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA. Dalma Deak, Cristina Pop, Andreea-Alina Zimta, Ancuta Jurj, Alexandra Ghiaur, Sergiu Pasca, Delia Dima, Patric Teodorescu, Catalin Constantinescu, Mihnea Zdrengea, Daniel Coriu, Alina Tanase,

Ioana Berindan-Neagoe, Delia Dima, Hermann Einsele, **Ciprian Tomuleasa**. *Frontiers in Immunology*, 2019, in press. **impact factor: 5.165**.

67. BASOPHILIA SUGGESTS AN 'ACCELERATED PHASE' IN THE EVOLUTION OF CHRONIC CALR-POSITIVE PRIMARY MYELOFIBROSIS TOWARDS ACUTE MYELOID LEUKEMIA. Jerome Dobrowolski, Sergiu Pasca, Patric Teodorescu, Ioana Rus, Cristina Selicean, Ana Maria Rosu, Ioana Berindan-Neagoe, Bogdan Fetica, Adrian Trifa, Anca Bojan, Mihnea Zdrengea, Bobe Petrushev, **Ciprian Tomuleasa**, Delia Dima. *Frontiers in Oncology*, 2019, in press, **impact factor: 5.165**.

68. LEAM *VERSUS* BEAM *VERSUS* CLV CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED/REFRACTORY LYMPHOMAS. RETROSPECTIVE COMPARISON OF TOXICITY AND EFFICACY ON 222 PATIENTS, ON BEHALF OF THE ROMANIAN SOCIETY FOR BONE MARROW TRANSPLANTATION. Andrei Colita, Anca Colita, Horia Bumbea, Adina Croitoru, Carmen Orban, Lavinia Eugenia Lipan, Oana Gabriela Craciun, Dan Soare, Cecilia Ghimici, Raluca Manolache, Ionel Gelatu, Ana Maria Vladareanu, Patric Teodorescu, Delia Dima, Sergiu Pasca, Anca Lupu, Daniel Coriu, **Ciprian Tomuleasa**, Alina Tanase. *Frontiers in Oncology* 2019; in press. **impact factor: 5.165**.

69. PROTEIN DYSREGULATION IN GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES. Liren Qian, Delia Dima, Jian Cen, Cristian Berce, Lajos Raduly, Alina Tanase, Bobe Petrushev, Ioana Berindan-Neagoe, Alexandru Irimie, Ancuta Jurj, Jian Liang Shen, **Ciprian Tomuleasa**. *Oncotarget*, in press. **impact factor: 5.168**.

70. GENETICALLY ENHANCED T LYMPHOCYTES AND THE INTENSIVE CARE UNIT. Tiberiu Tat, Huming Li, Catalin Constantinescu, Anca Onaciu, Sergiu Chira, Sergiu Pasca, Bobe Petrushev, Vlad Moisoiu, Wilhelm-Thomas Micu, Cristian Berce, Sebastian Tranca, Delia Dima, Ioana Berindan-Neagoe, Jianliang Shen, **Ciprian Tomuleasa**, Liren Qian. *Oncotarget* 2018, in press. **impact factor: 5.168**.

71. MOBILE HEALTH TECHNOLOGY FOR THE PERSONALIZED THERAPY OF HEMOPHILIA. Noemi Dirzu, Ionut Hotea, Melen Brinza, Mareike-Catrina Peters, Krisztina Gal, Louis Popescu, Cristina Blag, Mirela Marian, Eva Pal, Marilena

- Stanescu, Diana Cenariu, Cristina Tarniceriu, Margit Serban, Delia Dima, Daniel Coriu, **Ciprian Tomuleasa**. *Frontiers in Medicine*, 2021, in press, **impact factor: 5.091**.
72. COAGULOPATHY IN ACUTE PROMYELOCYTIC LEUKEMIA: CAN WE GO BEYOND SUPPORTIVE CARE? Bryan C. Hambley, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Medicine*, 2021, in press. **impact factor: 5.091**.
73. MODERN APPROACHES TO HEMOPHILIA MANAGEMENT: GENE THERAPY AND BEYOND. Daniel Coriu, Noemi Dirzu, Alina-Andreea Zimta, Bryan C. Hambley, Laszlo Nemes, Xiaojing Liu, Gabriel Ghiaur, Johny Mahlangu, **Ciprian Tomuleasa**. *Frontiers in Medicine*, 2022, in press. **impact factor: 5.091**.
74. RESULTS OF A TWO-ARM PHASE II CLINICAL TRIAL USING POST-TRANSPLANTATION CYCLOPHOSPHAMIDE FOR PREVENTION OF GRAFT-VERSUS-HOST DISEASE IN HAPLOIDENTICAL AND MISMATCHED UNRELATED DONORS HEMATOPOIETIC STEM CELL TRANSPLANTATION. Sameh Gaballa, Isabell Ge, Riad El-Fakih, Jonathan E. Brammer, **Ciprian Tomuleasa**, Sa A. Wang, Dean Lee, Demetrios Petropoulos, Kai Cao, Gabriela Rondon, Julianne Chen, Aimee Hammerstrom, Lindsey Lombardi, Gheath Al-atrash, Martin Korbling, Oran Betul, Partow Kebriaei, Sairah Ahmed, Nina Shah, Katyoun Rezvani, David Marin, Qaiser Bashir, Amin Alousi, Yago Nieto, Muzaffar Qazilbash, Chitra Hosing, Uday Popat, Elizabeth J. Shpall, Issa Khouri, Richard E. Champlin, Stefan O. Ciurea. *Cancer*, 2016; 122(21):3316-3326. **impact factor 5.068**.
75. EDITORIAL: FLOW CYTOMETRY – A POWERFUL TOOL FOR DIAGNOSIS AND THERAPY MONITORING IN HEMATOLOGY AND IMMUNOLOGY. Cenariu M, Grewal R, Bumbea H, Sauma D, Tomuleasa C. *Frontiers in Medicine* 2023, in press, impact factor: 5.058.
76. EXOSOME-CARRIED MICRORNA-BASED SIGNATURE AS A CELLULAR TRIGGER FOR THE EVOLUTION OF CHRONIC LYMPHOCYTIC LEUKEMIA INTO RICHTER SYNDROME. Ancuta Jurj, Laura Pop, Bobe Petrushev, Delia Dima, Ioana Rus, Adrian Trifa, Bogdan Fetica, Grigore Gafencu, Sonia Selicean, Daiana Temian, Cristian Berce, Alexandra Sacu, Alin Moldovan, Andrei Colita, Horia Bumbea, Alina Tanase, Angela Dascalescu, Nicolae Leopold, Emil Burzo, Mihnea Zdrenghia,

Rares Stiufiuc, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. Critical Reviews in Clinical Laboratory Sciences, 2018, in press. **impact factor: 5.34.**

77. PERIODONTAL DISEASE MIGHT BE A RISK FACTOR FOR GRAFT VERSUS HOST DISEASE. A SYSTEMATIC REVIEW. Alexandru Mester, Andra Mester, Sebastian Tranca, **Ciprian Tomuleasa**, Alina Tanase. Critical Reviews in Hematology and Oncology, 2020, in press. **impact factor: 5.012.**

78. PROGRESS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION AND CELLULAR THERAPIES. Diana Cenariu, Horia Bumbea, Anca Colita, Catalin Constantinescu, Minodora Desmirean, Sabina Iluta, Daniel Lysak, Alberto Mussetti, Ioana Tichil, Alina Tanase, **Ciprian Tomuleasa**. Journal of Clinical Medicine, 2022, in press. impact factor: 4.964.

79. HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS AND SUBSEQUENT ACUTE HEPATIC FAILURE IN A MULTIPLE MYELOMA PATIENT FOLLOWING COMBINATION THERAPY WITH IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE. Catalin Constantinescu, Bobe Petrushev, Ioana Rus, Horia Stefanescu, Otilia Frasinariu, Simona Margarit, Delia Dima, **Ciprian Tomuleasa**. Journal of Personalized Medicine, 2022, in press. **impact factor: 4.945**

80. MEDICAL APPLICATIONS OF HYDROGEN IN HEMATOLOGICAL DISEASES. Liren Qian, Zhengcheng Wu, Jian Cen, Sergiu Pasca, **Ciprian Tomuleasa**. Oxidative Medicine and Cellular Longevity, 2019, in press. **impact factor: 4.868.**

81. REAL WORLD PATIENT OUTCOMES WITH BLINATUMOMAB AND INOTUZUMAB IN ADULT REALPSED / REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA : A RETROSPECTIVE ANALYSIS FROM TWO ROMANIAN ONCOLOGY CENTERS. Ion Antohe, Amalia Titieanu, Vlad Andrei Cianga, Cosmin Minciună, Cătălin Dănăilă, Alina Daniela Tanase, Iuliu Ivanov, Loredana Dragoș, Mihaela Zlei, Mihaela Mentel, **Ciprian Tomuleasa**, Anamaria Bancos, Manuela Ciocoiu and Angela Dăscălescu. Frontiers in Pharmacology 2025, in press, impact factor: 4.8.

82. SYBERGISTIC EFFECT OF HUMAN CHORIONIC GONADOTROPIN AND GRANULOCYTE COLONY STIMULATING FACTOR IN THE MOBILIZATION OF HSCS IMPROVES OVERALL SURVIVAL AFTER PBSCT IN A PRECLINICAL MURINE MODEL. ARE WE FAR ENOUGH FOR THERAPY ? Cismaru Cosmin-Andrei, **Tomuleasa Ciprian**, Jurj Ancuta, Chira Sergiu, Isacescu Ecaterina, Cismaru Gabriel, Gherman Madalina, Tomuleasa Diana, Muntean Raluca, Berindan-Neagoe Ioana. Stem Cell Reviews and Reports, 2023, **impact factor: 4.8**, in press.
83. OPTIMIZATION OF TYROSINE KINASE INHIBITOR-LOADED GOLD NANOPARTICLES FOR STIMULI-TRIGGERED ANTILEUKEMIC DRUG RELEASE. Andra-Sorina Tatar, Timea Nagy-Simon, Adrian Bogdan Tigu, **Ciprian Tomuleasa**, Sanda Boca. Journal of Functional Biomaterials., 2023, **impact factor: 4.8**.
84. MACROPHAGE POLARIZATION IN CHRONIC LYMPHOCYTIC LEUKEMIA: NURSE-LIKE CELLS ARE THE CARETAKERS OF CLL CELLS. Oana Mesaros, Laura Jimbu, Alexandra Neaga, Cristian Marian Popescu, Iulia Berceanu, **Ciprian Tomuleasa**, Bogdan Fetica, Mihnea T. Zdrenghia. Biomedicine, 2020, submitted for publication. **impact factor: 4.717**.
85. MICRORNA 155 IMPLICATION IN M1 POLARIZATION. THE IMPACT IN INFLAMMATORY DISEASES. Sergiu Pasca, Maria-Ancuta Jurj, Bobe Petrushev, **Ciprian Tomuleasa**, Dana Matei. Frontiers in Immunology, **impact factor: 4.716**.
86. MICRORNA 155 IMPLICATION IN M1 POLARIZATION. THE IMPACT IN INFLAMMATORY DISEASES. Sergiu Pasca, Maria-Ancuta Jurj, Bobe Petrushev, **Ciprian Tomuleasa**, Dana Matei. Frontiers in Oncology 2020, in press, **impact factor: 4.716**.
87. EXPLORING NOVEL FRONTIERS IN CANCER THERAPY. Bogdan Tigu, **Ciprian Tomuleasa**. Biomedicines 2024, **impact factor : 4.7**.
88. TRANSFORMING GROWTH FACTOR BETA-MEDIATED MICROMECHANICS MODULATES DISEASE PROGRESSION IN PRIMARY MYELOFIBROSIS. Patric Teodorescu, Sergiu Pasca, Ancuta Jurj, Jon Petur Joelsson, Sonia Selicean, Cristian Moldovan, Raluca Munteanu, Anca Onaciu, Mihail Buse, Bogdan Tigu, Sebastian Rauch, Rares Stiufiuc, Minodora Desmirean, Delia Dima, Jon Thor Bergthorsson, Bobe Petrushev,

Cristian Berce, Stefan Ciurea, Gabriel Ghiaur, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine, 2020, in press, **impact factor 4.658**.

89. AZACYTIDINE PLUS OLAPARIB FOR RELAPSED ACUTE MYELOID LEUKEMIA, INELIGIBLE FOR INTENSIVE CHEMOTHERAPY, DIAGNOSED WITH A SYNCHRONOUS MALIGNANCY. Sabina Iluta, Ancuta Jurj, Grigore Gafencu, Sergiu Pasca, Andreea Terec, Patric Teodorescu, Cristina Selicean, Ciprian Jitaru, Maria Iordache, Catalin Constantinescu, Richard Feder, Raluca Munteanu, Delia Dima, Diana Gulei, Tudor Ciuleanu, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine, 2021, in press. **impact factor: 4.486**.
90. ALLOGENEIC STEM CELL TRANSPLANTATION FOR ADULT T-CELL LEUKEMIA/LYMPHOMA – ROMANIAN EXPERIENCE. Alina D. Tanase, Andrei Colita, Oana G. Craciun, Lavinia Lipan, Zsofia Varady, Laura Stefan, Adela Ranate, Sergiu Pasca, Horia Bumbea, Mihaela Andreescu, Viola Popov, Alexandru Bardas, Daniel Coriu, Anca Roxana Lupu, **Ciprian Tomuleasa**, Anca Colita, Olivier Hermine. Journal of Clinical Medicine, 2020, in press. **impact factor: 4.674**.
91. DATABASE-GUIDED ANALYSIS FOR IMMUNOPHENOTYPIC DIAGNOSIS AND FOLLOW-UP OF ACUTE MYELOID LEUKEMIA WITH RECURRENT GENETIC ABNORMALITIES. Carmen-Mariana Aanei, Richard Veyrat-Masson, Cristina Selicean, Mirela Marian, Lauren Rigollet, Adrian Pavel Trifa, **Ciprian Tomuleasa**, Adrian Serban, Mohamad Cherry, Pascale Flandrin-Gresta, Emmanuelle Tavernier, Denis Guyotat-Catafal. Frontiers in Oncology, 2021, in press. **impact factor: 4.448**.
92. FLOW CYTOMETRY OF CD5-POSITIVE HAIRY CELL LEUKEMIA. Diana Cenariu, Ioana Rus, Jon Thor Bergthorsson, Ravnit Grewal, Mihai Cenariu, Victor Greiff, Bogdan Tigu, Delia Dima, Cristina Selicean, Bobe Petrushev, Mihnea Zdrenghea, Jonathan Fromm, **Ciprian Tomuleasa**. Molecular Diagnosis and Therapy 2023, in press. **impact factor: 4.476**.
93. TET2 RS1548483 NSP ASSOCIATING WITH SUSCEPTIBILITY TO MOLECULARLY ANNOTATED POLYCYTHEMIA VERA AND PRIMARY MYELOFIBROSIS. Diana Lighezan, Anca Bojan, Mihaela Iancu, Raluca Pop, Ștefana Gligor-Popa, Florin Tripon, Adriana Cosma, **Ciprian Tomuleasa**, Delia Dima, Mihnea

- Zdrenghia, Bogdan Fetica, Ioana Ioniță, Ildikó Gaál, Simona Vișan, Andreea-Manuela Mirea, Radu Popp, Mira Florea, Cătălin Araniciu, Lucian Petrescu, Ioan Pop, Claudia Bănescu, Adrian Trifa. *Journal of Personalized Medicine* in press. **impact factor: 4.433**.
94. LONG NON-CODING RNAS IN MYELOID MALIGNANCIES. Alina-Andreea Zimta, **Ciprian Tomuleasa**, George Calin, Ioana Berindan-Neagoe, *Frontiers in Oncology*, 2019, in press. **impact factor: 4.416**.
95. KRAS/NRAF/BRAF MUTATIONS AS POTENTIAL TARGETS IN MULTIPLE MYELOMA. Sergiu Pasca, **Ciprian Tomuleasa**, Gabriel Ghiaur, Patric Teodorescu, Delia Dima, Vlad Moisoiu, Cristian Berce, Cristina Stefan, Aaron Ciechanover, Hermann Einsele. *Frontiers in Oncology*, 2019, in press. **impact factor: 4.416**.
96. CURRENT THERAPEUTICS IN THE MANAGEMENT OF HEMOPHILIA – A CONSENSUS VIEW BY THE ROMANIAN SOCIETY OF HEMATOLOGY. Ionut Hotea, Melen Brinza, Cristina Blag, Alina-Andreea Zimta, Noemi Dirzu, Ioana Rus, Dragos Apostu, Horea Benea, Mirela Marian, Alexandru Mester, Sergiu Pasca, Sabina Ioana Iluta, Patric Teodorescu, Ciprian Jitaru, Mihnea Zdrenghia, Anca Bojan, Tunde Torok-Vistai, Radu Niculescu, Cristina Tarniceriu, Delia Dima, Margit Serban, **Ciprian Tomuleasa**, Daniel Coriu. *Annals of Translational Medicine*, 2021, in press. **impact factor: 4.421**.
97. IN-DEPTH ANALYSIS FOR TKI-DRIVEN REAL WORLD MANAGEMENT OF 201 CML PATIENTS USING TFR. Mihnea-Lucian Micu, Simion-Florin Cira, Mihnea Zdrenghia, Anca Bojan, Delia Dima, Andrada Parvu, Tunde Torok-Vistai, Anca Vasilache, Laura Urian, Anamaria Bancos, Laura Jimbu, Oana Mesaros, Maria Santa, Diana Lighezan, Andrei Ivancuta, Adrian Trifa, Cristina Selicean, Ioana Rus, **Ciprian Tomuleasa**. *Frontiers in Pharmacology* 2025, in press. **impact factor : 4.4**.
98. EXTRAMEDULLARY HEMATOPOIESIS OF THE LIVER AND SPLEEN. Diana Cenariu, Sabina Iluta, Alina-Andreea Zimta, Bobe Petrushev, Liren Qian, Noemi Dirzu, **Ciprian Tomuleasa**, Horia Bumbea, Florin Zaharie. *Journal of Clinical Medicine*, 2021, in press, **impact factor: 4.241**.

99. SERS-BASED DNA METHYLATION PATTERN FOR THE POINT-OF-CARE DIFFERENTIAL DIAGNOSIS OF MALIGNANT LYMPHADENOPATHY. INITIAL ASSESSMENT COMPARING REACTIVE LYMPH NODES, B-CELL LYMPHOMAS, T-CELL LYMPHOMAS AND METASTATIC MELANOMA. Andrei Stefanu, Vlad Moisoiu, Stefania D. Iancu, Minodora Desmirean, Bobe Petrushev, Ancuta Jurj, Liviuta Budisan, Bogdan Fetica, Andrei Roman, Gina Dobie, Cristina Turcas, Mihnea Zdrenghea, Patric Teodorescu, Sergiu Pasca, Doina Piciu, Delia Dima, Nicolae Leopold, **Ciprian Tomuleasa**. Colloids and Surfaces B: Biointerfaces, in press. **impact factor: 4.389**.
100. GOLD NANOPARTICLES ENHANCE THE EFFECT OF TYROSIN KINASE INHIBITORS IN ACUTE MYELOID LEUKEMIA THERAPY. Bobe Petrushev, Sanda Boca, Timea Simon, Cristian Berce, Ioana Frinc, Delia Dima, Sonia Selicean, Grigore-Aristide Gafencu, Alina Tanase, Mihnea Zdrenghea, Adrian Florea, Sorina Suarasan, Liana Dima, Raluca Stanciu, Ancuta Jurj, Anca Buzoianu, Andrei Cucuianu, Simion Astilean, Alexandru Irimie, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. International Journal of Nanomedicine, 2016; 11:641-60. **impact factor: 4.383**.
101. IN VIVO ASSESSMENT OF BONE MARROW TOXICITY FOR GOLD NANOPARTICLE-BASED BIOCONJUGATES IN CRL:CD1(ICR) MICE. Cristian Berce, Ciprian Lucan, Bobe Petrushev, Sanda Boca, Mirela Miclean, Orsolya Sarpataki, Simion Astilean, Anca Buzoianu, **Ciprian Tomuleasa**, Anca Bojan. International Journal of Nanomedicine, 2016; 11:4261-73. **impact factor: 4.383**.
102. STRUCTURAL CHANGES OF RESIN BASEC COMPOSITES IN SALIVA OF PATIENTS WITH LEUKEMIA BEFORE STARTING CHEMOTHERAPEUTIC REGIMEN. Alexandru Mester, Marioara Moldovan, Stanca Cuc, Ioan Petean, **Ciprian Tomuleasa**, Andra Piciu, Cristian Dinu *, Simion Bran, Florin Onisor. Polymers, 2022, in press. **impact factor: 4.329**.
103. IBRUTINIB MONOTHERAPY AS BRIDGE-TO-TRANSPLANT FOR RELAPSED/REFRACTORY PRIMARY OCULO-CEREBRAL LYMPHOMAS. ROMANIAN EXPERIENCE. Dalma Deak-Mihaly, Sabina Iluta, Sergiu Pasca, Ciprian Jitaru, Andrei Roman, Alexandra Andries, Monica Padurariu-Covit, Anca Vasilache, Anca Bojan, Angela Dascalescu, Ion Antohe, Anca Colita, Andrei Colita, Delia Dima,

- Alina Tanase, **Ciprian Tomuleasa**. Journal of Clinical Medicine, 2021, in press. **impact factor: 4.241**.
104. THE PREDICTIVE ROLE OF MODIFIED EARLY WARNING SCORES IN 174 HEMATOLOGICAL PATIENTS AT RISK FOR TRANSFER TO THE INTENSIVE CARE UNIT. Catalin Constantinescu, Sergiu Pasca, Sabina Iluta, Grigore Gafencu, Maria Santa, Ciprian Jitaru, Patric Teodorescu, Delia Dima, Mihnea Zdrenghea, **Ciprian Tomuleasa**. Journal of Clinical Medicine, 2021, in press, **impact factor: 4.241**.
105. EDITORIAL: NOVEL DRUGS TARGETING THE MICROENVIRONMENT AND THE EPIGENETIC CHANGES IN HEMATOPOIETIC MALIGNANCIES. Diana Gulei, **Ciprian Tomuleasa**, Liren Qian, Cristina Bagacean, Carlo M. Croce, Gabriel Ghiaur. Frontiers in Pharmacology 2020, in press. **impact factor: 4.225**.
106. SNAPSHOT LOOK AT CASTLEMAN DISEASE. Ciprian Jitaru, Natalia Zlampa, Delia Dima, Anca Bojan, Mihnea Zdrenghea, Laura Urian, David Keyes, Anamaria Bancos, Maria Santa, Andrei Ivancuta, Bobe Petrushev, Madalina Nistor, Bogdan Tigu, Bogdan Fetica, Maria Puiu, Mihai-Stefan Muresan, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine 2025, in press. impact factor : 4.2.
107. NANOPHARMACOLOGY IN TRANSLATIONAL HEMATOLOGY AND ONCOLOGY. **Ciprian Tomuleasa**, Cornelia Braicu, Alexandra Irimie, Lucian Craciun, Ioana Berindan-Neagoe. Int J Nanomedicine. 2014;9:3465-79. **impact factor: 4.195**.
108. REVERSING CHEMORESISTANCE OF MALIGNANT GLIOMAS STEM CELLS USING GOLD NANOPARTICLES. Anamaria Orza, Olga Soritau, **Ciprian Tomuleasa**, Liliana Olenic, Adrian Florea, Ovidiu Pana, Ioan Bratu, Eموke Pall, Stefan Florian, Dan Casciano, Alexandru S. Biris. International Journal of Nanomedicine 2013, 8:1-14. **impact factor: 4.195**
109. SORAFENIB FOR THE TREATMENT OF SOLID MALIGNANCIES. WHAT ABOUT THE CANCER MICROENVIRONMENT? **Tomuleasa C**, Cucuianu A, Aldea M, Berindan-Neagoe I. International Journal of Nanomedicine. 2013; 8:4043-4. **impact factor: 4.195**.

110. MRI-BASED IDENTIFICATION OF UNDIFFERENTIATED CELLS. LOOKING AT THE TWO FACES OF JANUS. **Tomuleasa C**, Florian IS, Berce C, Irimie A, Berindan-Neagoe I, Cucuianu A. International Journal of Nanomedicine 2014, 9:865-6. **impact factor: 4.195.**
111. DOSE INTENSITY AND AUTOLOGOUS STEM CELL TRANSPLANTATION AS SALVAGE THERAPY FOR PEDIATRIC CNS MALIGNANCIES. Seiji Kojima, Andrei Cucuianu, Yoshiyuki Takahashi, Ioana Berindan-Neagoe, Ioan Stefan Florian, **Ciprian Tomuleasa**. International Journal of Nanomedicine 2014, 9:3247-8. **impact factor: 4.195.**
112. SMALL MOLECULES AGAINST B-RAF (BRAF) VAL600GLU (V600E) SINGLE MUTATION. Florin Zaharie, Roxana Cojocneanu-Petric R, Mihai Muresan, Ioana Frinc, Delia Dima, Bobe Petrushev, Alina Tanase, Cristian Berce, Mariana Chitic, Ioana Berindan-Neagoe, Valentina Pileczki, Alexandru Irimie, **Ciprian Tomuleasa**. International Journal of Nanomedicine 2015, 9:3247-8. **impact factor: 4.195.**
113. THE MALIGNANT ROLE OF EXOSOMES AS NANOCARRIERS OF RARE RNA SPECIES. Alina-Andreea Zimta, Olafur Eysteinn Sigurjonsson, Diana, **Ciprian Tomuleasa**. International Journal of Molecular Sciences, 2020, in press. **impact factor: 4.183.**
114. FIBROBLAST DYNAMICS AS AN IN VITRO SCREENING PLATFORM FOR ANTI-FIBROTIC DRUGS IN PRIMARY MYELOFIBROSIS. **Ciprian Tomuleasa**, Sonia Selicean, Grigore Gafencu, Bobe Petrushev, Daiana Temian, Laura Pop, Cristian Berce, Ancuta Jurj, Adrian Trifa, Ana Maria Rosu, Sergiu Pasca, Lorand Magdo, Delia Dima, Mihnea Zdrenghea, Ioana Frinc, Anca Bojan, Alina Tanase, Ioana Berindan-Neagoe, Gabriel Ghiaur, Stefan Ciurea. Journal of Cellular Physiology 2018, in press. **impact factor: 4.155.**
115. DAY 15 AND DAY 33 MINIMAL RESIDUAL DISEASE ASSESSMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA TREATED ACCORDING TO THE BFM ALL IC 2009 PROTOCOL. SINGLE-CENTER EXPERIENCE OF 133 CASES. Letitia Elena Radu, Sergiu Pasca, Andrei Colita, **Ciprian Tomuleasa**, Codruta Popa, Catalin Serban, Anca Gheorghe, Andreea Serbanica, Cristina Jercan, Andra Marcu, Ana Bica, Patric Teodorescu, Catalin Constantinescu, Bobe Petrushev, Minodora Asan, Cerasela

- Jardan, Mihaela Dragomir, Alina Tanase, Anca Colita. *Frontiers in Oncology*, 2020, in press, **impact factor: 4.137**.
116. SERS-BASED ASSESSMENT OF MRD IN ACUTE PROMYELOCYTIC LEUKEMIA? Cristina Turcas, Vlad Moisoiu, Andrei Stefancu, Ancuta Jurj, Stefania D. Iancu, Patric Teodorescu, Sergiu Pasca, Anca Bojan, Adrian Trifa, Sabina Iluta, Andreea Zimta, Bobe Petrushev, Mihnea Zdrenghea, Horia Bumbea, Daniel Coriu, Delia Dima, Nicolae Leopold, **Ciprian Tomuleasa**. *Frontiers in Oncology*, in press. **impact factor: 4.137**.
117. CD19-TARGETED, RAMAN-TAGGED GOLD NANOURCHINS AS THERANOSTIC AGENTS AGAINST ACUTE LYMPHOBLASTIC LEUKEMIA. Andra-Sorina Tatar, Ancuta Jurj, **Ciprian Tomuleasa**, Adrian Florea, Ioana Berindan-Neagoe, Dana Cialla-May, Juergen Popp, Simion Astilean, Sanda Boca. *Colloids and Surfaces B: Biointerfaces*, 2019, in press. **impact factor: 3.997**.
118. CHARACTERIZATION OF EXTRACHROMOSOMAL CIRCULAR DNA IN PATIENTS WITH ACUTE MYELOID LEUKEMIA. PROOF-OF-CONCEPT REPORT USING COHORTS FROM BEIJING AND SHANGHAI. Liren Qian, Xinxin Xia, Jiabin Liu, Xiaoping Chen, Yu Liu, Xiaona Wang, Sabina Iluta, Sergiu Pasca, Diana Gulei, Ciprian Tomuleasa. *Annals of Translational Medicine*, 2022, in press. **impact factor: 3.932**.
119. USE OF VENO-VENOUS HEMODIAFILTRATION AS RENAL REPLACEMENT THERAPY FOR SEVERE TUMOR LYSIS SYNDROME. Radu Tomai, Antonia Oancea, Ciprian Tomuleasa, Delia Dima. *Diagnostics* 2024, submitted for publication. **impact factor: 3.992**.
120. THE NON-MUTATIONAL CAUSES OF HEMOPHILIA: NON-CODING RNAS AND ACQUIRED HEMOPHILIA. Alina-Andreea Zimta, Ionut Hotea, Melen Brinza, Cristina Blag, Sabina Iluta, Catalin Constantinescu, Atamyrat Bashimov, Elisabeth-Antonia Marchis-Hund, Alexandra Coudsy, Laetitia Muller-Mohnssen, Noemi Dirzu, Diana Gulei, Delia Dima, Margit Serban, Daniel Coriu, **Ciprian Tomuleasa**. *Frontiers in Medicine*, 2021, **impact factor: 3.9**, in press.
121. RARE WITHIN RARE: A GIRL WITH SEVERE HAEMOPHILIA A AND TURNER SYNDROME. Cristina Blag, Margit Serban, Cristina Emilia Ursu, Cristina

- Popa, Adina Traila, Cristian Jinca, **Ciprian Tomuleasa**, Mădălina Bota, Smaranda Teodora Arghirescu. Journal of Clinical Medicine 2023, in press. **impact factor: 3.9.**
122. ANESTHESIA MANAGEMENT FOR GIANT INTRAABDOMINAL TUMORS: A CASE SERIES STUDY. Olga Grajdieru, Cristina Petrisor, Constantin Bodolea, **Ciprian Tomuleasa**, Catalin Constantinescu. Journal of Clinical Medicine 2024, in press. **impact factor: 3.9.**
123. ERYTHROPOIESIS: THE ROLE OF SIGNALLING PATHWAYS, GENETIC AND EPIGENETIC REGULATORS. Ioana Tichil, Ileana Mitre, Anca Bojan, Mihnea Zdrenghea, **Ciprian Tomuleasa**, Diana Cenariu. Journal of Clinical Medicine 2024, **impact factor: 3.9**, in press.
124. ADVANCES IN CELL AND IMMUNE THERAPIES FOR MELANOMA. Tanase Timis, Sanda Buruiana, Delia Dima, Madalina Nistor, Ximena Maria Muresan, Diana Cenariu, Adrian-Bogdan Tigiu, **Ciprian Tomuleasa**. Biomedicines 2025, in press. **impact factor: 3.9.**
125. INSIGHTS INTO PEDIATRIC GATA2-RELATED MDS. UNVEILLING CHALLENGES IN CLINICAL PRACTICE. Andra Daniela Marcu, Ana Maria Bica, Cristina Georgiana Jercan, Letitia Elena Radu, Andreea Nicoleta Serbanica, Dumitru Jordan, Andrei Colita, Simona Olimpia Dima, Ciprian Tomuleasa, Alina Daniela Tanase, Anca Colita. Biomedicines 2025, **impact factor : 3.9.** in press.
126. SHEAR WAVE ELASTROGRAPHY FOR DISTINGUISHING CERVICAL LYMPH NODE MALIGNANCY : A PROSPECTIVE, OBSERVATIONAL STUDY. Dragos Tarmure, Manuela Lenghel, Mindra Badea, Horațiu Rotar, **Ciprian Tomuleasa**, Bobe Petrushev, Emil Boțan, Mădălina Anca Moldovan, Rares Roman, Alexandru Florin Badea. Biomedicines 2025, in press. impact factor : **3.9.**
127. THE ROLE OF PATHOLOGY DEPARTMENT IN THE PRE-ANALYTICAL PHASE OF MOLECULAR ANALYSES. Sergiu Susman, Ioana Berindan-Neagoe, Bobe Petrushev, Radu Pirlog, Ioan-Stefan Florian, Carmen-Mihaela Mihiu, Cristian Berce, Lucian Craciun, Ravnit Grewal, **Ciprian Tomuleasa**, Cancer Management and Research, in press, **impact factor: 3.851.**

128. TARGETING THE MICROENVIRONMENT IN MDS: THE FINAL FRONTIER. Patric Teodorescu, Sergiu Pasca, Delia Dima, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Pharmacology* 2020, in press. **impact factor: 3.845.**
129. TARGETING THE MICROENVIRONMENT IN MDS: THE FINAL FRONTIER. Patric Teodorescu, Sergiu Pasca, Delia Dima, **Ciprian Tomuleasa**, Gabriel Ghiaur. *Frontiers in Pharmacology* 2020, in press. **impact factor: 3.845.**
130. A NARRATIVE VIEW OF CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ACUTE LEUKEMIAS. Dalma Deak, Nicolae Gorcea-Andronic, Valentina Sas, Patric Teodorescu, Sabina Iluta, Sergiu Pasca, Ionut Hotea, Cristina Turcas, Simona Galdean, Jakob Steinheber, Ioana Rus, Sebastian Rauch, Raluca Munteanu, Ancuta Jurj, Bobe Petrushev, Cristina Selicean, Mirela Marian, Olga Soritau, Alexandra Andries, Andrei Roman, Delia Dima, Alina Tanase, **Ciprian Tomuleasa**. *Annals of Translational Medicine*, 2021, in press, **impact factor: 3.689.**
131. USEFULNESS OF SALINE SEALING IN PREVENTING PNEUMOTHORAX AFTER CT-GUIDED BIOPSIES OF THE LUNG. Andrei Roman, Andreea Brozba, Alexandru Necula, Delia Doris Muntean, Paul Kubelac, Zsolt Fekete, **Ciprian Tomuleasa**, Csaba Csutak, Diana, Feier, Roxana Pintican, Catalin Vlad. *Diagnostics* 2023, in press. **impact factor: 3.61.**
132. NANOSCLAE INVESTIGATION OF DNA DEMETHYLATION IN LEUKEMIA CELLS BY MEANS OF ULTRASENSITIVE VIBRATIONAL SPECTROSCOPY. Anca Onaciu, Valentin Toma, Cristian Moldovan, Adrian Bogdan Țigu, Diana Cenariu, Carina Culic, Rareș Mario Borșa, Luca David, Gabriela Fabiola Știufiuc, Romulus Tetean, **Ciprian Tomuleasa**, Rareș Ionuț Știufiuc. *Sensors*, 2022, in press. **impact factor: 3.576.**
133. COVID-19 IMPACT ON CHRONIC MYELOID LEUKEMIA PATIENTS. Dana Raluca Arbore, Simona Maria Galdean, Delia Dima, Ioana Rus, David Kegyes, Raluca Geanina Ababei, Daniela Dragancea, Radu Andrei Toma, Adrian Pavel Trifa, **Ciprian Tomuleasa**. *Journal of Personalized Medicine*, 2022, in press. **impact factor: 3.508.**
134. B CELLS VERSUS T CELLS IN THE TUMOR MICROENVIRONMENT OF MALIGNANT LYMPHOMAS. ARE THE LYMPHOCYTES PLAYING THE ROLES OF MUHAMMAD ALI VERSUS GEROGGE FOREMAN IN ZAIRE 1974? Minodora

Desmirean, Sebastian Rauch, Ancuta Jurj, Sergiu Pasca, Sabina Iluta, Patric Teodorescu, Cristian Berce, Andreea-Alina Zimta, Cristina Turcas, Irene Paris, Jakob Steinheber, Cedric Richlitzki, Bogdan Fetica, Delia Dima, Alina Tanase, Bobe Petrushev, **Ciprian Tomuleasa**. Journal of Clinical Medicine, 2020, in press. **impact factor: 35.**

135. EMERGENCY-DRIVEN MULTIPLE INVASIVE PROCEDURES IN HAEMOPHILIA. Cristina Emilia Ursu, Margit Serban, Jenel Marian Patrascu, Daniel Coriu, Jenel Marian Patrascu Jr, Ioana Ionita, Adina Traila, **Ciprian Tomuleasa**, Delia Savescu, Melen Brinza, Codrut Ivan, Teodora Smaranda Arghirescu. Life 2024, in press. **impact factor: 3.2.**
136. ROP-ET: A PROSPECTIVE PHASE III TRIAL INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN ESSENTIAL THROMBOCYTHEMIA PATIENTS WITH LIMITED TREATMENT OPTIONS. Jean-Jacques Kiladjian, Francisca Ferrer Marin, Haifa Kathrin Al-Ali, Alberto Alvarez Larran, Eloise Beggiato, Maria Bieniaszewska, Massimo Breccia, Veronika Buxhofer-Ausch, Olga Cerna, Ana-Manuela Crisan, Catalin Doru Danaila, Valerio De Stefano, Konstanze Doehner, Victoria Empson, Joanna Gora-Tybor, Martin Griesshammer, Sebastian Grosicki, Paola Guglielmelli, Jose Valentin Garcia Gutierrez, Florian Heidel, Arpad Illés, **Ionut-Ciprian Tomuleasa**, Chloe James, Steffen Koschmieder, Maria-Theresa Krauth, Kurt Krejcy, Mihaela-Cornelia Lazaroiu, Jiri Mayer, Zsolt György Nagy, Franck-Emmanuel Nicolini, Francesca Palandri, Vassiliki Pappa, Andreas Johannes Reiter, Tomasz Sacha, Stefanie Schlager, Stefan Schmidt, Evangelos Terpos, Martin Unger, Albert Woelfler, Blanca Xicoy Cirici, Christoph Klade. Annals of Hematology 2023, in press, **impact factor: 3.5.**
137. OUTCOMES OF HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR LYMPHOMA WITH MELPHALAN-BASED CONDITIONING. Jonathan E. Brammer, Issa Khouri, Sameh Gaballa, Paolo Anderlini, Sairah Ahmed, Celina Ledesma, **Ciprian Tomuleasa**, Chitra Hosing, Richard E. Champlin, Stefan O. Ciurea. Biology of Blood and Marrow Transplantation 2015, 2016; 22(3):493-8. **impact factor: 3.404.**
138. PAEDIATRIC HOSPITALIZED IMMUNE THROMBOCYTOPENIA IN THE REAL-LIFE OF RECENT VIRAL INFECTION OUTBREAKS. Cristina Emilia Ursu, Margit Serban, Cristian Marius Jinca, Estera Boeriu, Ioana Ionita, Daniel Coriu, Melen

Brinza, **Ciprian Tomuleasa**, Teodora Smaranda Arghirescu. Life 2025, in press. **impact factor: 3.4.**

139. CUTANEOUS WOUND HEALING USING POLYMERIC SURGICAL DRESSINGS BASED ON CHITOSAN, SODIUM HYALURONATE AND RESVERATROL. Cristian Berce, Isabella Rigo, Bobe Petrushev, Lucia Tefas, Gheorghe Ungureanu, Mihai-Stefan Muresan, Olga Soritau, Cornel Catoi, Alexandru Irimie, **Ciprian Tomuleasa**. Colloids and Surfaces B. Biointerfaces, in press 2017. **impact factor: 3.387.**
140. CASTLEMAN'S DISEASE IN THE HIV-ENDEMIC SETTING. Esam-Rajab Mahroug, Candice Sher-Locketz, Minodora-Silvia Desmirean, Emmanuel-Akinola Abayomi, **Ciprian Tomuleasa**, Ravnit Grewal. Cancer Management and Research, 2018, in press. **impact factor: 3.351.**
141. SYSTEMIC SIDE-EFFECTS OF FDA AND/OR EMA-APPROVED TARGETED THERAPIES FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES. Catalin Constantinescu, Sergiu Pasca, Alina-Andreea Zimta, Tiberiu Tat, Ioana Rus, Patric Teodorescu, Sabina Iluta, Alina Tanase, Olafur Sigurjonsson, Hermann Einsele, **Ciprian Tomuleasa**. Journal of Clinical Medicine, 2020, in press. **impact factor: 3.303.**
142. OUTCOMES OF CAR T CELL THERAPY RECIPIENTS ADMITTED TO THE ICU: IN SEARCH FOR A STANDARD OF CARE – A BRIEF OVERVIEW AND METANALYSIS OF PROPORTIONS. Cătălin Constantinescu, Vlad Moisoiu, Bogdan Tigiu, David Kegyes, Ciprian Tomuleasa. Journal of Clinical Medicine 2023, submitted for publication. **impact factor: 3.303.**
143. REAL-WORLD TREATMENT PATTERNS AND CLINICAL OUTCOMES IN PATIENTS WITH AML UNFIT FOR FIRST-LINE INTENSIVE CHEMOTHERAPY. Miyakawa Yoshitaka, Sanford David, Tomuleasa Ciprian, Hsiao Hui Hua, Enjeti Anoop, Gimenez Conca Alberto, Bernal del Castillo Teresa, Girshova Larisa, Martelli Maria, Guvenc Birol, Delgado Alexander, Duan Yinghui, Llamas Cynthia D, Lee Je-Hwan. Leukemia and Lymphoma, 2021, in press. **impact factor: 3.28.**
144. ANTIPROLIFERATIVE EFFECT OF NOVEL PLATINUM(II) AND PALLADIUM(II) COMPLEXES ON HEPATIC TUMOR STEM CELLS IN VITRO. Natalia Miklášova, Eva Fischer-Fodor, Peter Lönnecke, **Ciprian Ionut Tomuleasa**,

Piroska Virag, Maria Perde-Schrepler, Roman Mikláš, Luminita Silaghi-Dumitrescu, Evamarie Hey-Hawkins. *European Journal of Medicinal Chemistry* 2012, 49C:41-47.

impact factor: 3.27

145. SYNTHESIS AND *IN VITRO* ANTIPROLIFERATIVE ACTIVITY OF NEW THIAZOLO [4,5-B]PHENOTHIAZINE AGAINST HUMAN LEUKEMIA. Balasz Brem, Emese Gal, Luiza Gaina, Castelia Cristea, Luminita Silaghi-Dumitrescu, Eva Fischer-Fodor, **Ciprian Ionut Tomuleasa**, Adriana Grozav, Valentin Zaharia, Lorena Filip. *International Journal of Molecular Sciences*, in press. **impact factor 3.257.**

146. MESENCHYMAL STEM CELLS IN MYELOPROLIFERATIVE DISORDERS – FOCUS ON PRIMARY MYELOFIBROSIS. Sonia Selicean, **Ciprian Tomuleasa**, Ravnit Grewal, Graca Almeida-Porada, Ioana Berindan-Neagoe. *Leukemia and Lymphoma*, 2018, accepted for publication. **impact factor: 3.093.**

147. LABEL-FREE SERS ON BLOOD GENOMICS DNA. TOWARDS THE DETECTION OF ACUTE MYELOID LEUKEMIA IN PATIENTS UNDERGOING ALLOGENEIC STEM CELL TRANSPLANTATION. Vlad Moisoiu, Andrei Stefancu, Stefania Iancu, Tudor Moisoiu, Luminita Loga, Lucia Dican, Cristian Alecsa, Imre Boros, Anca Jurj, Delia Dima, Cristina Bagacean, Romulus Tetean, Emil Burzo, **Ciprian Tomuleasa**, Florin Elec, Nicolae Leopold. *Analytical and Bioanalytical Chemistry*, 2019, in press. **impact factor: 3.307.**

148. MICRORNA-21 INHIBITS SERPINI 1, A GENE WITH NOVEL TUMOR SUPPRESSIVE EFFECTS IN GASTRIC CANCER. Sumitaka Yamanaka, Alexandru V Olaru, Delgermaa Luvsanjav, Fangmei An, Zhe Jin, Rachana Agarwal, **Ciprian Tomuleasa**, Irinel Popescu, Sorin Alexandrescu, Delia Dima, Mihaela Chivu-Economescu, Elizabeth A. Montgomery, Michael Torbenson, Christine Vazquez, Stephen J Meltzer, Florin M Selaru. *Digestive and Liver Diseases*, 2012, 44(7)589-596. **impact factor: 3.05**

149. CAPILLARY LEAK SYNDROME ASSOCIATED WITH ANAPLASTIC T CELL LYMPHOMA AND TRANSCUTANEOUS EXUDATION. Radu Tomai, Antonia Oancea, Ciprian Tomuleasa, Delia Dima. *Diagnostics* 2024, submitted for publication. **impact factor: 3.0.**

150. “LAZARUS RESPONSE” WHEN FETO-MATERNAL MICROCHIMERISM KICKS IN ... SPONTANEOUS REMISSION IN REFRACTORY PRIMARY MEDIASTINAL B CELL LYMPHOMA FOLLOWING TWIN PREGNANCY. Radu Tomai, Sabina Iluta, Adrian-Bogdan Tigu, Madalina Nistor, Anamaria Bancos, Diana Cenariu, Ciprian Jitaru, Sergiu Patcas, Delia Dima, David Keyyes, Sanda Buruiana, Mihnea Zdrengeha, Alina Tanase, **Ciprian Tomuleasa**, Romeo Micu. *Diagnostics* 2024, in press. **impact factor: 3.0**.
151. Hsiao HH, Enciso Olivera LJ, Ito T, Bui C, Sanford D, Duan Y, Garbayo Guijarro MB, Martelli M, Bernal del Castillo T, Girshova L, Delgado A, Enjeti A, Tomuleasa C, Guvenc B, Llamas C, Lee JH, Gimenez Conca A. Healthcare resource utilization trends in patients with acute myeloid leukemia ineligible for intensive chemotherapy receiving first-line systemic treatment or best supportive care: A multicenter international study. *European Journal of Haematology* 2022, in press. impact factor: 2.997.
152. LOW MOLECULAR WEIGHT HEPARINS (LMWH) AND SYNTHETIC FACTOR X INHIBITORS CAN IMPAR THE OSSEOINTEGRATION OF TITANIUM IMPLANT IN ANIMAL MODEL. Dragos Apostu, Bianca Berechet, Daniel Oltean-Dan, Alexandru Mester, Bobe Petrushev, Catalin Popa, Madalina Luciana Gherman, Adrian Bogdan Tigu, **Ciprian Ionut Tomuleasa**, Lucian Barbu-Tudoran, Horea Rares Ciprian Benea, Doina Piciu. *Medicina* 2022, in press. impact factor: 2.94.
153. THE EFFECT OF CATIONS AND DNA METHYLATION ON THE ABSORPTION OF DNA ON SILVER NANOPARTICLES. Stefania D. Iancu, Vlad Moisoiu, Bogdan A. Tigu, Andrei Stefanu, Oana M. Biro, **Ciprian Tomuleasa**, Nicolae Leopold. *PloS One* 2025, in press. **impact factor : 2.9**.
154. THE NEW ERA OF NANOTECHNOLOGY, AN ALTERNATIVE TO CHANGE CANCER TREATMENT. Ancuta Jurj, Laura Pop, Cornelia Braicu, **Ciprian Tomuleasa**, Claudia Gherman, Ioana Berindan-Neagoe. *Drug Design, Development and Therapy*, in press. **impact factor: 2.881**.
155. MICRORNAS FOR THE DIAGNOSIS OF GRAFT VERSUS HOST DISEASE. **Ciprian Tomuleasa**, Shigeo Fuji, Andrei Cucuianu, Markus Kapp, Sonia Selicean, Alina Tanase, Delia Dima, Bobe Petrushev, Valentina Pileczki, Ioana Berindan-Neagoe,

Alexandru Irimie, Hermann Einsele. *Annals of Hematology* 2015, 94(7):1081-92. **impact factor: 2.866.**

156. DESIGN OF FLT3 INHIBITOR GOLD NANOPARTICLE CONJUGATES AS POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA. Timea Simon, **Ciprian Tomuleasa**, Anca Bojan, Ioana Berindan-Neagoe, Sanda Boca, Simion Astilean. *Nanoscale Research Letters* 2015, 2015; 10(1):466. **impact factor: 2.78.**
157. CLINICOPATHOLOGICAL ANALYSIS OF A CASE SERIES OF PERIPHERAL T-CELL LYMPHOMAS, NOT OTHERWISE SPECIFIED, OF LYMPHOEPITELIOID VARIANT (LENNER'S LYMPHOMA). A CENTRAL EUROPEAN SINGLE-CENTER STUDY. Grigore-Aristide Gafencu, Sonia Selicean, Bobe Petrushev, Andrei Cucuianu, Delia Dima, Ioana Frinc, Alexandru Irimie, Rares Buiga, Valentina Pileczki, Ioana Berindan-Neagoe, Cristian Berce, **Ciprian Tomuleasa**. *Human Pathology*, 2016; 53:192-4. **impact factor: 2.769.**
158. INFLAMMATION, TUMORAL MARKERS AND INTERLEUKIN-17, -10 AND -6 PROFILES IN PANCREATIC ADENOCARCINOMA AND CHRONIC PANCREATITIS. Alina Tantau, Daniel-Corneliu Leucuta, Marcel Tantau, Emil Botan, Roxana Zaharie, **Ionut-Ciprian Tomuleasa**. *Digestive Diseases and Sciences*, 2020, in press. **impact factor: 2.751.**
159. DARATUMUMAB IN RELAPSED OR REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA. **Ciprian Tomuleasa**, Robert Peter Gale. *Blood Science* 2025, in press. **impact factor: 2.7.**
160. LARGE INTRON INVERSIONS IN ROMANIAN PATIENTS WITH HEMOPHILIA A – FIRST REPORT. Melen Brinza, Andra Grigore, Mihaela Dragomir, Dumitru Jardan, Cerasela Jardan, Paul Balanescu, Claudia Cristina Tarniceriu, Oana Viola Badulescu, Cristina Blag, **Ciprian Tomuleasa**, Adina Traila, Margit Serban, Daniel Coriu. *Medicina* 2023, in press. **impact factor: 2.6.**

161. THE ROLE OF TGF- β IN TISSUE MICROENVIRONMENT: A POTENTIAL NEW THERAPEUTIC APPROACH IN HCC TREATMENT. Bhavna Rani, Yuan Cao, Andrea Malfettone, **Ciprian Tomuleasa**, Isabel Fabregat, Gianluigi Giannelli. World Journal of Gastroenterology 2014, 20(15):4128-4140. **impact factor: 2.547.**
162. REPOSITIONING METFORMIN IN CANCER: GENETICS, DRUG TARGETS AND NEW WAYS OF DELIVERY. Mihaela Aldea, Lucian Craciun, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Gabriel Kacso, Ioan-Stefan Florian, Carmen Crivii. Tumour Biology. 2014; 35(6):5101-10. **impact factor: 2.518.**
163. THE INFLUENCE OF METHYLATING MUTATIONS ON CHOOSING ACUTE MYELOID LEUKEMIA CHEMOTHERAPY. PRELIMINARY ANALYSIS ON 58 PATIENTS. Sergiu Pasca, Cristina Turcas, Ancuta Jurj, Patric Teodorescu, Sabina Iluta, Ionut Hotea, Cristina Selicean, Bogdan Fetica, Bobe Petrushev, Vlad Moisoiu, Alina-Andreea Zimta, Valentina Sas, Catalin Constantinescu, Mihnea Zdrenghea, Delia Dima, **Ciprian Tomuleasa**. Diagnostics, 2020, in press. **impact factor: 2.489.**
164. CLINICAL REMISSION FOR AN ELDERLY PATIENT WITH A MASSIVE PRIMARY CUTANEOUS PERIPHERAL T-CELL LYMPHOMA-NOS OF THE EYE, FOLLOWING COMBINATION CHEMOTHERAPY WITH ETOPOSIDE PLUS COP. Sabina Iluta, Dragos-Alexandru Termure, Bobe Petrushev, Mindra-Eugenia Badea, Madalina Moldovan-Lazar, Manuela Lenghel, Csaba Csutak, Andrei Roman, Sergiu Pasca, Cedric Richlitzki, Sebastian Rauch, Delia Dima, **Ciprian Tomuleasa**, Rares-Calin Roman. Diagnostics, 2020, in press. **impact factor: 2.489.**
165. GELATIN COATED GOLD NANOPARTICLES AS CARRIERS OF FLT3 INHIBITOR DRUGS FOR ACUTE MYELOID LEUKEMIA TREATMENT. Sorina Suarasan, Timea Simon, Sanda Boca, **Ciprian Tomuleasa**, Simion Astilean. Chemical Biology and Drug Design, 2016; 87(6):927-35. **impact factor: 2.485.**
166. USE OF FLOW CYTOMETRY IN THE PHENOTYPIC AND DIAGNOSIS OF HODGKIN'S LYMPHOMA. Ravnit Grewal, Manogari Chetty, Emmanuel Akinola Abayomi, **Ciprian Tomuleasa**, Jonathan R. Fromm. Cytometry Part B. Clinical Cytometry, 2018l in press. **impact factor: 2.474.**
167. PERIODONTAL DISEASE AND VON WILLEBRAND DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS. Alexandru Mester, Leonardo

Mancini, Enrico Marchetti, Mihaela Baciut, Simion Bran, Ondine Lucaciu, Grigore Baciut, **Ciprian Tomuleasa**, Sergiu Pasca, Andra Piciu, Andrada Voina-Tonea, Horia Opris, Daiana Antoaneta Prodan, Florin Onișor. Applied Sciences, 2021, in press. **impact factor: 2.474.**

168. NOVEL PALADIUM (III) COMPLEXES INFLUENCE PROMININ-1/CD133 EXPRESSION AND STEM CELL FACTOR RELEASE IN TUMOR CELLS. Natalia Miklášova, Eva Fischer-Fodor, Roman Mikláš, Mihai Cenariu, Piroska Virag, **Ciprian I Tomuleasa**, Corina Tatomir, Ioana Berindan-Neagoe, Ferdinand Devínsky. Molecules (Basel), 2017; 22(4). pii: E561. **impact factor 2.465.**
169. METFORMIN, ARSENIC TRIOXIDE, OLANZAPINE AND BETA-BLOCKERS AS NEW HORIZONS FOR GLIOBLASTOMA THERAPY. HAS TIME COME FOR CLINICAL TRIALS? Marco Carmignani, Mihaela Aldea, Olga Soritau, Anna Rita Volpe, Alexandru Irimie, Ioan-Stefan Florian, **Ciprian Tomuleasa**, Bobe Petrushev, Adriana Baritchii, Gianina Crisan, Guido Valle. Journal of biological regulators and homeostatic agents 2014, 28(1):1-15. **impact factor: 2.406.**
170. SEROPREVALENCE OF BARTONELLA SPECIES, COXIELLA BURNETII AND TOXOPLASMA GONDII AMONG PATIENTS WITH HEMATOLOGICAL MALIGNANCIES: A PILOT STUDY IN ROMANIA. Chelsea J. Messinger, Eugen Gurzau, Ed Breitschwerdt, **Ciprian Tomuleasa**, Sally Trufan, Ricardo G. Maggi, Ioana Berindan-Neagoe, Peter Rabinowitz. Zoonoses and Public Health 2017, in press. **impact factor: 2.369.**
171. THE USE OF ROTATION TO FENTANYL IN CANCER-RELATED PAIN. Delia Dima, **Ciprian Tomuleasa**, Ioana Frinc, Sergiu Pasca, Lorand Magdo, Mihai Muresan, Ioana Berindan-Neagoe, Cosmin Lisencu, Alexandru Irimie, Mihnea Zdrengea. Journal of Pain Research, 2017; 10:341-348. **impact factor: 2.363.**
172. JAK2 V617F ALLELE BURDEN CONTRIBUTED TO THE OCCURANCE OF MAJOR THROMBOSIS IN POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA. Adrian Trifa, Claudia Banescu, Cristian Voina, Stefana Popa, Tunde Torok-Vistai, Anca Bojan, Delia Dima, Mihnea Zdrengea, Bogdan Fetica, Simona Visan, **Ciprian Tomuleasa**, Bogdan Pop, Viola Popov, Mihaela Andreescu, Radu Popp. Blood Cells, Molecules and Disease 2018, in press. **impact factor: 2.331.**

173. ADULT ACUTE MEGAKARYOBLASTIC LEUKEMIA. RARE ASSOCIATION WITH CYTOPENIAS OF UNDETERMINED SIGNIFICANCE AND P210 AND P190 *BCR-ABL* TRANSCRIPTS. Delia Dima, Liana Oprita, Ana-Maria Rosu, Bobe Petrushev, Adrian Trifa, Cristina Selicean, Vlad Moisoiu, Ioana Rus, Mihnea Zdrenghea, **Ciprian Tomuleasa**. *OncoTargets and Therapy*, in press. **impact factor: 2.311.**
174. BCR-ABL T315I MUTATION, A NEGATIVE PROGNOSTIC FACTOR FOR THE TERMINAL PHASE OF CHRONIC MYELOGENOUS LEUKEMIA TREATED WITH FIRST AND SECOND LINE TYROSINE KINASE INHIBITORS, MIGHT BE AN INDICATOR OF ALLOGENEIC STEM CELL TRANSPLANTATION AS THE TREATMENT OF CHOICE. **Ciprian Tomuleasa**, Delia Dima, Ioana Frinc, Mariana Patiu, Bobe Petrushev, Andrei Cucuianu, Ioana Berindan-Neagoe. *Leukemia and Lymphoma* 2015, 56(2):546-7. **impact factor: 2.301.**
175. BASIC KNOWLEDGE ON BCR-ABL1 POSITIVE EXTRACELLULAR VESICLES. Ancuta Jurj, Sergiu Pasca, Patric Teodorescu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. *Biomarkers in Medicine*, 2020, in press, **impact factor: 2.268.**
176. IMPLICATION OF TET2 IN CAR-T CELL ACTIVITY AND TARGET'S RESPONSE TO CAR-T CELL THERAPY. LESSONS LEARNED FROM T-CELLS. Sergiu Pasca, Ancuta Jurj, Catalin Constantinescu, Mihnea Zdrenghea, **Ciprian Tomuleasa**. *Critical Reviews in Immunology*, 2021, in press. **impact factor: 2.237.**
177. THE LAUREN CLASSIFICATION HIGHLIGHTS THE ROLE OF EPITHELIAL-TO-MESENCHYMAL TRANSITION IN CARCINOGENESIS: AN IMMUNOHISTOCHEMISTRY STUDY OF THE STAT3 AND ADHESION MOLECULES EXPRESSION. Sergiu Susman, Raphaelle Barnoud, Frederique Bibeau, Francesco Borini, Marc Pocard, **Ciprian Tomuleasa**, Jean-Christophe Sabourin. *Journal of Gastrointestinal and Liver Diseases* 2015, 24(1):77-83. **impact factor: 2.202.**
178. DO LYMPHOMAS HAVE AN AUTOIMMUNE BACKGROUND AND HOW CAN WE INCREASE THE SENSITIVITY OF THE DIAGNOSIS OF PRIMARY PANCREATIC LYMPHOMA WITH RELATIVELY SMALL SAMPLES ? **Ciprian Tomuleasa**, Emmanuel Akin-Abayomi, Delia Dima, Cristian Tefas, Alexandru Irimie,

- Bobe Petrushev, Ioana Frinc, Ravnit Grewal. Journal of Gastrointestinal and Liver Diseases 2015, 24(3):391-2. **impact factor: 2.202.**
179. EXOSOME-CARRIED MICRORNA-375 INHIBITS CANCER CELL PROGRESSION VIA BCL-2 BLOCKING IN COLON CANCER. Mihai-Stefan Muresan, Florin Zaharie, Bobe Petrushev, Cristian Berce, Grigore Gafencu, Sonia Selicean, Ancuta Jurj, Roxana Cojocneanu-Petric, Cosmin-Ioan Lisencu, Laura-Ancuta Pop, Valentina Pileczki, Dan Eniu, Mihai-Andrei Muresan, Roxana Zaharie, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Alexandru Irimie. Journal of Gastrointestinal and Liver Diseases 2015, 2015; 24(4):435-43. **impact factor: 2.202.**
180. HENOCH SCHONLEIN PURPURA AND CLOSTRIDIUM DIFFICILE INFECTION, A HEMATOLOGISTS' POINT OF VIEW. Delia Dima, **Ciprian Tomuleasa**, Mihnea Zdrenghea. Journal of Gastrointestinal and Liver Diseases, 2016; 25(3):411.. **impact factor: 2.202.**
181. HOW TO DIAGNOSE AND TREAT A CANCER OF UNKNOWN PRIMARY SITE. **Ciprian Tomuleasa**, Mihai Stefan Muresan, Florin Zaharie, Laura Pop, Zsolt Fekete, Delia Dima, Ioana Frinc, Adrian Trifa, Cristian Berce, Ancuta Jurj, Ioana Berindan-Neagoe, Mihnea Zdrenghea, Tudor Ciuleanu. Journal of Gastrointestinal and Liver Diseases, 2017; 26(1):69-79. **impact factor: 2.202.**
182. ANTIPROLIFERATIVE AND APOPTOTIC IN VITRO EFFECTS OF LIDOCAINE ON HUMAN HEPATOCARCINOMA CELLS. Ancuta Jurj, **Ciprian Tomuleasa**, Tiberiu Tat, Ioana Berindan-Neagoe, Stefan V. Vesa, Daniela Ionescu. Journal of Gastrointestinal and Liver Diseases, 2017; 26(1):45-50. **impact factor: 2.202.**
183. ADOPTIVE CELLULAR THERAPIES IN MULTIPLE MYELOMA. David Kegyes, Bogdan Borlea, Marc Damian, Adrian Bogdan Tigu, Madalina Nistor, Diana Cenariu, Raluca Munteanu, Diana Gulei, Angela Dascalescu, Ion Antohe, Alina Tanase, Evangelos Terpos, Hermann Einsele, **Ciprian Tomuleasa**. Best Practice & Research Clinical Hematology 2025, in press. **impact factor: 2.2.**
184. ADOPTIVE CELLULAR THERAPIES IN NON-HODGKIN'S LYMPHOMAS. David Kegyes, Bogdan Borlea, Marc Damian, Adrian Bogdan Tigu, Madalina Nistor, Diana Cenariu, Raluca Munteanu, Diana Gulei, Angela Dascalescu, Ion Antohe, Alina Tanase, Anca Colita, Nazar Shokun, Tetiana Skrypets, Hermann Einsele, Massimo

Federico, **Ciprian Tomuleasa**. Best Practice & Research Clinical Hematology 2025, in press. **impact factor: 2.2**.

185. NEXT GENERATION SEQUENCING-BASED CHARACTERIZATION OF THE INVASION BY ANATOMICAL CONTIGUITY IN A PRIMARY OSSEOUS DIFFUSE LARGE B-CELL LYMPHOMA. Florin Zaharie, Laura-Ancuta Pop, Bobe Petrushev, Mihai-Stefan Muresan, Dan Eniu, Bogdan Fetica, Doina Piciu, Ioana Rus, Delia Dima, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. Histology and Histopathology, 2018, in press. **impact factor: 2.025**.
186. MANAGEMENT OF RENAL EXTRASKELETAL CHONDROSARCOMA. Vitalie Gherman, **Ciprian Tomuleasa**, Catalina Bungardean, Dan Vasile Stanca, Victor Dan Ona, Bogdan Feciche, Alexandru Irimie, Ioan Coman. BMC Surgery 2014, 2014; 14:107. **impact factor: 1.97**.
187. CHRONIC GRANULAMATOUS DERMATOSIS AS A PRESENTING SIGN FOR CUTANEOUS T-CELL LYMPHOMAS. Andrei Cucuianu, Bobe Petrushev, Doinita Crisan, Rares Buiga, Ana Maria Rosu, Delia Dima, **Ciprian Tomuleasa**. European Journal of Dermatology 2015, 25(2):210. **impact factor: 1.92**.
188. GOLD NANOPARTICLES CONJUGATED WITH CISPLATIN/DOXORUBICINE/ CAPECITABINE LOWER THE CHEMORESISTANCE OF HEPATOCELLULAR CARCINOMA-DERIVED CANCER CELLS. **Ciprian Tomuleasa**, Olga Soritău, Anamaria Orza, Mircea Ducea, Bobe Petrushev, Ofelia Mosteanu, Sergiu Susman, Adrian Florea, Eموke Pall, Mihaela Aldea, Gabriel Kacso, Victor Cristea, Ioana Berindan-Neagoe, Alexandru Irimie. Journal of Gastrointestinal and Liver Diseases 2012, 21(2):187-196. **impact factor: 1.81**
189. ISOLATION AND CHARACTERIZATION OF HEPATIC CANCER CELLS WITH STEM LIKE PROPERTIES FROM HEPATOCELLULAR CARCINOMA, **Ciprian Tomuleasa**, Olga Sorițău, Dan Rus Ciucă, Teodora Pop, Daniela Todea, Ofelia Moșteanu, Bogdan Pintea, Vasile Foris, Sergiu Sușman, Gabriel Kacsó, Alexandru Irimie, Journal of Gastrointestinal and Liver Diseases, 2010; 19(1):61-67. **impact factor: 1.81**

190. ALDH AS A TUMOR MARKER FOR PANCREATIC CANCER. **Ciprian Tomuleasa**, Ofelia Mosteanu, Sergiu Susman, Victor Cristea. Journal of Gastrointestinal and Liver Diseases 2011, 20(4):443-446. **impact factor: 1.81**
191. PARASITAEMIA AND HEMATOLOGICAL ALTERATIONS IN MALARIA-AFFECTED REFUGEES IN SOUTH AFRICA. Nonzwakazi Pretty Ntombela, Joyce Mahlako Tsoka-Gwegweni, Uchenna Okafor, Andrei Bibirigea, Alexandru Irimie, **Ciprian Tomuleasa**. South African Medical Journal, 2015, in press. **impact factor: 1.712**
192. COMPARISON OF PERIPHERAL BLOOD STEM CELL MOBILIZATION WITH FILGRATIM VERSUS PEGFILGRASTIM IN LYMPHOMA PATIENTS – SINGLE CENTER EXPERIENCE. Lavinia Lipan, Andrei Colita, Laura Stefan, Carmen Calugaroiu, Catalin Serban, **Ciprian Tomuleasa**, Sergiu Pasca, Anca Colita, Alina Tanase. Journal of the Balkan Union of Oncology 2021; 26(3): 1080-1087. **impact factor: 1.695.**
193. PROSPECTIVE INVESTIGATION OF PAIN ASSOCIATED WITH ULTRASOUND AND COMPUTED TOMOGRAPHY-GUIDED PERCUTANEOUS BIOPSIES IN ONCOLOGICAL PATIENTS. Andrei Roman, Federica Palego, Patriciu Achimas-Cadariu, Catalin Vlad, Alexandra Andries, **Ciprian Tomuleasa**, Vlad Alexandru Gata, Roxana Pintican, Patricia Maria Rada, Diana Feier. Medical Ultrasonography, 2020, in press. **impact factor: 1.674.**
194. SORAFENIB FOR ADVANCED STAGE HEPATOCELLULAR CARCINOMA. **Ciprian Tomuleasa**, Victor Cristea, Alexandru Irimie. European Journal of Gastroenterology and Hepatology, 2012, 24(3):346-347. **impact factor: 1.66**
195. BASELINE CHARACTERISTICS OF A NATIONWIDE COHORT OF PEDIATRIC PATIENTS WITH ACUTE LEUKEMIAS OF DOWN SYNDROME. Valentina Sas, Cristina Blag, Sergiu Pasca, Gheorghe Popa, Mirela Marian, Cristina Schnell, Daniela Voda, Smaranda-Teodora Arghirescu, Patric Teodorescu, Sabina Iluta, Cristina Turcas, Cristina Selicean, Anca Bojan, Mihnea Zdrenghea, Margit Serban, Delia Dima, Gabriela Zaharie, Anca Colita, Sorin Man, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology, 2020, in press, **impact factor: 1.6.**
196. RISK FACTORS AND OUTCOMES OF ANAEMIA AND BLOOD TRANSFUSIONS IN PLASTIC SURGERY PATIENTS. Ioana Tichil, Teodora Tichil,

Ioan Stefan Haplea, **Ciprian Tomuleasa**, Lucian Fodor, Ileana Mitre. Journal of International Medical Research 2024, in press. **impact factor: 1.6.**

197. MATRIX-METALLOPROTEINASE-2 PREDICTS ARTERIOVENOUS FISTULA FAILURE IN HAEMODIALYSIS PATIENTS. Dacian Tirinescu, **Ciprian Tomuleasa**, Laura Pop, Dan Vladutiu, Crina Rusu, Dana Moldovan, Alina Potra, Ina Kacso. Therapeutic Apheresis and Dialysis, 2017, in press, **impact factor: 1.529.**
198. TOPICAL CORTICOSTEROIDS, A VIABLE SOLUTION FOR ORAL GRAFT VERSUS HOST DISEASE? A SYSTEMATIC INSIGHT ON RANDOMIZED CLINICAL TRIALS. Arin Sava, Andra Piciu, Sergiu Pasca, Alexandru Mester, **Ciprian Tomuleasa**. Medicina (Kaunas), 2020, in press. **impact factor: 1.5.**
199. SILTUXIMAB IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: REAL WORLD EXPERIENCE FROM GREECE AND ROMANIA. Ciprian Jitaru, Argyris Symeonidis, Sorina Badelita, Eirini Katodritou, Andrei Colita, Anastasia Mpanti, Anamaria Bancos, Bogdan Tigiu, Petra Rotariu, Vasiliki Labropoulou, Mihai Stefan Muresan, Despina Fotiou, Bogdan Fetica, Bobe Petrushev, Delia Dima, Angela Dascalescu, Laura Urian, Dimitra Dalampira, Catalin Constantinescu, Mihnea Zdrenghea, Meletios A. Dimopoulos, **Ciprian Tomuleasa**, Evangelos Terpos. Journal of Hematology 2024, **impact factor: 1.5**, in press
200. DNMT3A R882 AND TET2/IDH1/2 MUTATIONS IMPACT BLAST CELL DIFFERENTIATION IN ACUTE MYELOID LEUKEMIA BUT NOT RESPONSE TO HYPOMETHYLATING AGENTS. Sergiu Pasca, Ancuta Jurj, **Ciprian Tomuleasa**, Mihnea Zdrenghea, Medicina, **impact factor: 1.2.** in press, 2020.
201. GOLD NANOPARTICLES CONJUGATED WITH RITUXIMAB FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA. Sanda Boca, Ciprian Lucan, Ioana Frinc, Bobe Petrushev, Timea Simon, Cristian Berce, Grigore-Aristide Gafencu, Delia Dima, Alina Tanase, Sonia Selicean, Valentina Pileczki, Laura Pop, Adrian Florea, Alexandru Irimie, Simion Astilean, Anca Bojan, Ioana Berindan-Neagoie, Mihnea Zdrenghea, **Ciprian Tomuleasa**. Farmacia 2016, in pres **impact factor: 1.162.**
202. TRANSTHORACIC ULTRASONOGRAPHY FOR THE FOLLOW-UP OF A CHRONIC LYMPHOCYTIC LEUKEMIA CHEMOTHERAPY-

- IMMUNOCOMPROMISED PATIENT PRIOR TO ALLOGENEIC STEM CELL TRANSPLANTATION. CASE REPORT. Ioana Frinc, Delia Dima, Mariana Chitic, Cristian Berce, Ioana Berindan-Neagoe, Tiberiu Tat, Alina Tanase, **Ciprian Tomuleasa**, Anca Bojan. Medical Ultrasonography, in press. **impact factor 1.167**.
203. A SYSTEMATIC APPROACH ON THE FREQUENCY OF LEFT LIP/PALATE IN PEDIATRIC PATIENTS WITH LEUKEMIA. Daiana Antoaneta Prodan, Simion Bran, Cristian Dinu, Grigore Baciut, **Ciprian Tomuleasa**, Andra Piciu, Alexandru Mester, Mihaela Baciut. Journal of Stomatology, Oral and Maxillofacial Surgery 2020, in press. **impact factor: 1.152**.
204. PARP INHIBITORS IN ACUTE MYELOID LEUKEMIA THERAPY: HOW A SYNTHETIC LETHALITY APPROACH CAN BE A VALID THERAPEUTIC ALTERNATIVE. Grigore Gafencu, **Ciprian Tomuleasa**, Gabriel Ghiaur. Medical Hypotheses, in press, **impact factor :1.136**.
205. A MATHEMATICAL MODEL OF CLONAL HEMATOPIESIS EXPLAINING PHASE TRANSITIONS IN MYELOID LEUKEMIA. Lorand Gabriel Parajdi, Xue Bai, David Kegyes, Ciprian Tomuleasa. Mathematical Medicine and Biology 2025, in press. **impact factor: 1.1**.
206. REDISTRIBUTION OF IRON TOWARDS DEPOSITS IN ERYTHROBLASTOPENIC ANEMIA AS A CONSEQUENCE OF DECREASED ERYTHROFERRONE PRODUCTION. Andrei Cucuianu, Mariana Patiu, Adrian P. Trifa, **Ciprian Tomuleasa**, Delia Dima. Medical Hypotheses 2014, 83(5):530-2. **impact factor: 1.054**.
207. RUXOLITINIB CONJUGATED WITH GOLD NANOPARTICLES, USED FOR TOPICAL ADMINISTRATION. AN ALTERNATIVE FOR TREATING ALOPECIA ? Sanda Boca-Farcau, Cristian Berce, Bobe Petrushev, Ancuta Jurj, Laura Pop, Grigore-Aristide Gafencu, Sonia Selicean, Vlad Moisoiu, Daiana Temian, Wilhelm-Thomas Micu, Simion Astilean, Cornelia Braicu, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe. Medical Hypotheses, in press. **impact factor: 1.03**.
208. HAPLOIDENTICAL DONORS: CAN FASTER TRANSPLANTATION BE LIFE-SAVING FOR PATIENTS WITH ADVANCED DISEASE ? Alina Tanase, **Ciprian Tomuleasa**, Alexandra Marculescu, Alexandru Bardas, Anca Colita, Carmen Orban,

Stefan Octavian Ciurea. Acta Haematologica 2015, 2016;135(4):211-6.. **impact factor: 0.994**

209. THE IMPORTANCE OF MICRO-RNAS IN THE STROMAL-BREAST CANCER CELL INTERPLAY. Sergiu Susman, **Ciprian Tomuleasa**, Zsolt Fekete, Brunella Pilato, Alexandru Irimie, Ioana Berindan-Neagoe. Cancer Biomarkers. 2014;14(2-3):137-44. **impact factor: 0.972**
210. HEMATOLOGY PATIENTS INFECTED WITH SARS-CoV-2 VIRUS, PRE-TREATED WITH ECULIZUMAB OR SILTUXIMAB, DEVELOP OLIGOSYMPTOMATIC DISEASE. Sabina Iluta, Sergiu Pasca, Delia Dima, Gabriela Mester, Laura Urian, Anca Bojan, Mihnea Zdrenghea, Adrian Trifa, Ovidiu Balacescu, **Ciprian Tomuleasa**. European Journal of Hospital Pharmacy, 2021, in press. **impact factor: 0.892**.
211. PARANEOPLASTIC SYNDROMES WITH CONNECTIVE TISSUE INVOLVEMENT. IT'S OT ALWAYS LUPUS ! T Timis, C Berce, A Duarte-Garcia, B Petrushev, V Cristea, **C Tomuleasa**. Journal of the Balkan Union of Oncology 2012, 17:417-421. **impact factor: 0.76**
212. MESENCHYMAL STEM CELL IRRADIATION IN CULTURE ENGAGES DIFFERENTIAL EFFECT OF HYPERFRACTIONATED RADIOTHERAPY FOR HEAD AND NECK CANCERS, **C Tomuleasa**, V Foris, O Sorițău, T Dicu, E Páll, I Brie, G Kacsó, Journal of Balkanic Union of Oncology, 2010; 15(2):348-356. **impact factor: 0.76**.
213. FUNCTIONAL AND MOLECULAR CHARACTERIZATION OF GLIOBLASTOMA MULTIFORME DERIVED CANCER STEM CELLS, **C Tomuleasa**, O Sorițău, D Rus Ciucă, H Ioani, S Sușman, M Petrescu, T Timis, D Cernea, G Kacsó, A Irimie, IS Florian, Journal of Balkan Union of Oncology, 2010; 15(3):583-591. **impact factor: 0.76**
214. METFORMIN PLUS TEMOZOLOMIDE-BASED CHEMOTHERAPY AS ADJUVANT TREATMENT FOR WHO GRADE III AND IV MALIGNANT GLIOMAS. O Soritau, **C Tomuleasa**, M Aldea, B Petrushev, S Susman, D Gheban, H Ioani, A Cocis, A Irimie, G Kacso, IS Florian. Journal of the Balkan Union of Oncology, 2011, 16:282-289. **impact factor: 0.76**

215. ANTIDIABETIC PHARMACOLOGY, A LINK BETWEEN METABOLIC SYNDROME AND NEURO-ONCOLOGY? M Aldea, **C Tomuleasa**, B Petrushev, S Susman, G Kacso, A Irimie, IS Florian, O Soritau. Journal of the Balkan Union of Oncology, 2011, 16:409-413. **impact factor: 0.76**
216. CANCER STEM CELLS AND MALIGNANT GLIOMAS. FROM PATHOPHYSIOLOGY TO TARGETED MOLECULAR THERAPY, IS Florian, **C Tomuleasa**, O Soritau, T Timis, G Kacso, A Irimie. Journal of the Balkan Union of Oncology, 2011, 16:16-23. **impact factor: 0.76**
217. ARSENIC TRIOXIDE SENSITIZES CANCER STEM CELLS TO CHEMORADIOTHERAPY – A NEW APPROACH IN THE TREATMENT OF INOPERABLE GLIOBLASTOMA MULTIFORME, **C Tomuleasa**, O Soritau, G Kacso, E Fischer-Fodor, A Cocis, H Ioani, M Petrescu, T Timis, D Cernea, P Virag, A Irimie, IS Florian, Journal of the Balkan Union of Oncology, 2010, 15:758-762. **impact factor: 0.76**
218. THE COLORECTAL CANCER STEM-LIKE CELL HYPOTHESIS. A PATHOLOGIST’S POINT OF VIEW. S Susman, **C Tomuleasa**, O Soritau, D Rus-Ciuca, J-C Sabourin, F Bibeau, A Irimie, R Buiga. Journal of the Balkan Union of Oncology, 2012, 17(2):230-236. **impact factor: 0.76**
219. THE ROLE OF DEPRESSION AND NEUROIMMUNE AXIS IN THE PROGNOSIS OF CANCER PATIENTS. Mihaela Aldea, Lucian Craciun, **Ciprian Tomuleasa**, Carmen Crivii. Journal of the Balkan Union of Oncology 2014, 19(1):5-14. **impact factor: 0.76**
220. THE ANDROGEN RECEPTOR AS KEY PLAYER IN METASTATIC HORMONE-REFRACTORY PROSTATE CANCERS. IMPLICATIONS FOR NEW TREATMENTS. Adina Nemes, **Ciprian Tomuleasa** , Gabriel Kacsó. Journal of the Balkan Union of Oncology 2014, 19(2): 357-364. **impact factor: 0.76**
221. MICRORNA-21 STIMULATES GASTRIC CANCER GROWTH AND INVASION BY INHIBITING THE TUMOR SUPPRESSOR EFFECTS OF PROGRAMMED CELL DEATH PROTEIN 4 AND PHOSPHATASE AND TENSIN HOMOLOG. Ling Li, Liya Zhou, Yuwen Li, Sanren Lin, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology 2014, 19(1):228-236. **impact factor: 0.76.**

222. CANCER STEM –LIKE CELLS: THE DARK KNIGHTS OF CLINICAL HEMATOLOGY AND ONCOLOGY. Ioana Frinc, Mihai-Stefan Muresan, Florin Zaharie, Ljubomir Petrov, Cristian Berce, Alexandra Irimie, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**. Journal of the Balkan Union of Oncology 2014, 19(2): 328-335. **impact factor: 0.76.**
223. METFORMIN PLUS SORAFENIB - AN ASSOCIATION THAT HIGHLY IMPACTS TEMOZOLOMIDE-REZISTANT GLIOBLASTOMA STEM-LIKE CELLS. Mihaela Aldea, Bobe Petrushev, Olga Soritau, **Ciprian Tomuleasa**, Ioana Berindan-Neagoe, Adriana Filip, Gabriela Chereches, Mihai Cenariu, Lucian Craciun, Corina Tatomir, Ioan-Stefan Florian, Carmen Crivii, Gabriel Kacso. Journal of the Balkan Union of Oncology 2014, 19(2): 502-511. **impact factor: 0.76.**
224. THE EFFECT OF ANAESTETIC ON NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN (NGAL) LEVELS AFTER ROBOTIC SURGICAL ONCOLOGY. Orsolya Mihály, Attila-Zoltan Mihály, Vitalie Gherman, Florin Zaharie, Sorana Bolboacă, Ciprian Chira, Constantin Bodolea, **Ciprian Tomuleasa**, Alexandru Irimie, Ioan Coman, Daniela Ionescu. Journal of the Balkan Union of Oncology 2015, 20(1):317-24. **impact factor: 0.76.**
225. MICRORNAS IN LIVER MALIGNANCIES. BASIC SCIENCE APPLIED IN SURGERY. Mihai-Stefan Muresan, Florin Zaharie, Anca Bojan, Bobe Petrushev, Roxana Cojocneanu-Petric, Alexandru Irimie, Grigore Gafencu, Sonia Selicean, Cristian Tefas, Andreea Cioca, Cristian Berce, Ioana Berindan-Neagoe, **Ciprian Tomuleasa**, Patriciu Achimas-Cadariu. Journal of the Balkan Union of Oncology 2015, 20(2):361-75. **impact factor: 0.76.**
226. ORAL SURGERY FOR COMBINED HAEMOPHILIA A AND B. THE DOS AND DON'TS IN A CLINICAL SCENARIO. Madalina Anca Lazar, Ovidiu Muresan, Calin Rares Roman, Delia Dima, Mihai Stefan Muresan, Gabriel Armencea, **Ciprian Tomuleasa**, Horatiu Rotaru. Ann Ital Chir, 2018; in press, **impact factor: 0.2.**
227. LAPAROSCOPIC SPLENECTOMY FOR HEREDITARY SPHEROCYTOSIS. Florin Zaharie, Mihai-Stefan Muresan, Cristina Blag, Roxana Zaharie, Claudiu Zdrehus, Mihnea Dragomir, Mihnea Zdreghea, Horia Bumbea, Alexandru Irimie, Delia Dima,

Ciprian Tomuleasa, Gheorghe Popa. Ann Ital Chir, submitted for publication. **impact factor: 0.2.**

228. EFFECTS OF Co GAMMA-RAYS ON HUMAN OSTEOGENITOR CELLS, **C.I. Tomuleasa**, V. Foris, Olga Sorițău, Emöke Páll, Eva Fischer-Fodor, V. Lung-Illes, Ioana Brie, Piroška Virág, Maria Perder-Schrepler, I.D. Postescu, Gabriela Cherecheș, Otilia Barbos, Corina Tatomir, Romanian Journal of Morphology and Embryology, 2009; 50(3):3-6.
229. PRIMUM NON NOCERE. IS STEM CELL RESEARCH READY FOR CLINICAL TRIALS ?, **Ciprian Tomuleasa**, Olga Sorițău, Sergiu Șuşman, Vasile Foris, Emöke Páll, Carmen Miha, Journal of the European Medical Students Association, 2009; 4(4):33-38.
230. ARSENIC TRIOXIDE PLUS CISPLATIN/ INTERFERON α -2B/ DOXORUBICIN/ CAPECITABINE COMBINATION CHEMOTHERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA, **Ciprian Tomuleasa**, Olga Sorițău, Teodora Pop, Eva Fischer-Fodor, Ofelia Mosteanu, Bobe Petrushev, Sergiu Susman, Mihaela Aldea, Monica Acalovschi, Alexandru Irimie, Gabriel Kacsó. Hematology Oncology and Stem Cell Therapy, 2011, 4(2):60-66.
231. ENHANCED CHEMORESISTANCE AND TUMOUR SPHERE FORMATION AS A LABORATORY MODEL FOR PERITONEAL MICROMETASTASIS IN EPITHELIAL OVARIAN CANCER, Olga Sorițău, **CI Tomuleasa**, Emöke Páll, Piroška Virág, Eva Fischer-Fodor, Gabriela Cherecheș, Otilia Barbos, Corina Tatomir, G Kacsó, A Irimie, Romanian Journal of Morphology and Embryology, 2010, 51(2):3-6.
232. CELLULAR INTERACTIONS IN PROSTATE CANCER GENESIS AND DISSEMINATION. LOOKING BEYOND THE OBVIOUS, **C Tomuleasa**, G Kacsó, S Șuşman, Olga Sorițău, Carmen Miha, A Irimie, Piroška Virág, Romanian Journal of Morphology and Embryology, 2010, 51(3):427-435.
233. PARANEOPLASTIC SYNDROMES AS KEY ELEMENTS OF DIFFERENTIAL DIAGNOSIS. Tanase Timis, Doru Tomesc, Bobe Petrushev, Claudiu Sas, Mihaela Aldea, **Ciprian Tomuleasa**. Journal of the European Medical Students Association, 2011, 6(1):7-12.

234. PLACENTAL STEM CELL DIFFERENTIATION INTO ISLETS OF LANGERHANS-LIKE GLUCAGON SECRETING CELLS. S Susman, Olga Soritau, D Rus-Ciuca, **C Tomuleasa**, VI Pop, Carmen Mihaela Mihiu. Romanian Journal of Morphology and Embryology, 2010, 51(4):733-738.
235. PANCREATIC EXOCRINE ADULT CELLS AND PLACENTAL STEM CELLS CO-CULTURE. WORKING TOGETHER IS ALWAYS THE BEST WAY TO GO. S Susman, Olga Soritau, D Rus-Ciuca, **C Tomuleasa**, R Buiga, D Mihiu, VI Pop, Carmen Mihaela Mihiu. Romanian Journal of Morphology and Embryology, 2011, 52(3 Suppl):999-1004.
236. METFORMIN PLUS PIAF COMBINATION CHEMOTHERAPY FOR HEPATOCELLULAR CARCINOMA. B. Petrushev, **C. Tomuleasa**, O. Soritau, M. Aldea, T. Pop, S. Susman, G. Kacso, I. Berindan-Neagoe, A. Irimie, V. Cristea. Experimental Oncology, 2012, 34(1):17-24.
237. ESTABLISHMENT OF AN EMBRYONIC STEM CELL LINE FROM BLASTOCYST STAGE MOUSE EMBRYOS. Eموke Pall, I Groza, M Cenariu, Olga Soritau, Elen Gocza, **C Tomuleasa**. Romanian Journal of Morphology and Embryology, 2011, 52(3 Suppl):1005-1010.
238. MINIMALLY INVASIVE ENUCLEATION WITH ZERO ISCHEMIA FOR MALIGNANCIES. THE CLUJ NAPOCA EXPERIENCE. Gherman V, **Tomuleasa C**, Irimie A, Coman I. American Journal of Case Reports 2013;14:511-2.
239. BICYTOPENIA AS A PARANEOPlastic SYNDROME FOR PSEUDOMYXOMA PERITONEI. HEMATOLOGIC MANIFESTATIONS OF A SUBTLE DISEASE. **Ciprian Tomuleasa**, Bobe Petrushev, Madalina Vedean, Alexandru Irimie, Florin Zaharie, Ana Maria Rosu, Delia Dima, Andrei Cucuianu, Ioana Frinc. International Journal of General Medicine 2015, 8:93-5.
240. FIRST SUCCESSFUL HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN ROMANIA. Alina Tanase, **Ciprian Tomuleasa**, Alexandra Marculescu, Alexandru Bardas, Anca Colita, Carmen Orban, Stefan Octavian Ciurea. Romanian Journal of Internal Medicine 2016, 2016 Sep 1;54(3):194-200.
241. PROCEEDINGS FROM THE 1ST INSIGHTS IN HEMATOLOGY SYMPOSIUM, CLUJ NAPOCA, ROMANIA MARCH 11-12, 2016. Anca Bojan, Ioana

Berindan-Neagoe, Stefan Ciurea, Delia Dima, Shigeo Fuji, Gabriel Ghiaur, Ravnit Grewal, Emmet McCormack, Alina Tanase, Adrian Trifa, Ciprian Tomuleasa. Romanian Journal of Internal Medicine 2016 Sep 1;54(3):157-160.

242. TRANSTHORACIC ULTRASONOGRAPHY FOR THE IMMUNOCOMPROMISED PATIENT. Ioana Frinc, Petru Ilies, Delia Dima, Alina Tanase, Ljubomir Petrov, Alexandru Irimie, Bobe Petrushev, Cristian Berce, Mihai-Stefan Muresan, Cosmin Lisencu, Ioana Berindan-Neagoe, Anca Bojan, **Ciprian Tomuleasa**. Romanian Journal of Internal Medicine, 2016, in press.
243. ADVANCES IN THE TREATMENT OF NEWLY DIAGNOSED PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMAS. Liren Qian, **Ciprian Tomuleasa**, Ioan-Alexandru Florian, Gheorghe Ungureanu, Ioan-Stefan Florian, Mihnea Zdrenghea, Jianliang Shen, Delia Dima. Blood Res 2017; 52(3): 159-166
244. HYPEREOSINIPHILIA IN A PATIENT WITH PERIPHERAL T-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED. Minodora Desmirean, Dalma Deak, Ioana Rus, Delia Dima, Sabina Iluta, Alexandra Preda, Tiberiu Moldovan, Andrei Roman, **Ciprian Tomuleasa**, Bobe Petrushev. Medicine and Pharmacy Reports, 2019, in press.
245. CORRELATION BETWEEN PREVALENCE OF T-CELL LYMPHOMAS AND ALCOHOL CONSUMPTION. Minodora Desmirean, Cedric Richlitzki, Sergiu Pasca, Patric Teodorescu, Sebastian Rauch, Jacob Steinheber, Sabina Iluta, Jiaxin Liu, Delia Dima, Ravnit Grewal, Weina Ma, Liren Qian, **Ciprian Tomuleasa**, Bobe Petrushev. Medicine and Pharmacy Reports, 2021, in press.
246. COEXISTENCE OF TRISOMY 8 AND 13 IN A NEWLY DIAGNOSED PATIENT WITH DIFFUSE LARGE B CELL NON-HODGKIN LYMPHOMA AND ACUTE MYELOID LEUKEMIA SECONDARY TO PRIMARY MYELOFIBOSIS. Horia Bumbea, Viola Maria Popov, Ciprian Tomuleasa, Meilin Omer, Camelia Dobrea, Irina Manea, Sabina Zurac, Cristiana Popp, Ion Dumitru, Madalina Simoiu, Bogdan Mastalier. Cureus 2022; 14(2): e22217.
247. EPYSQLI (SB12 ; BIOSIMILAR TO REFERENCE ECULIZUMAB) IN ASIAN AND NON-ASIAN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA : SUBGROUP ANALYSIS OF A GLOBAL PHASE III RANDOMIZED CONTROLLED TRIAL. Jun Ho Jang, **Ciprian Tomuleasa**, Hanna

Oliynyk, Theerin Lanamtieng, Jihye Park, Younsoo Kim, Jinah Jung, Paola Russo, Junichi Nishumura, Soo Min Lim, Régis Peffault de Latour. eJHaem 2025, in press. 248.

Under review:

PROGRESS IN ADENO-ASSOCIATED VIRUS-DELIVERED GENE THERAPY FOR INHERITED BLEEDING DISORDERS. Johnny N. Mahlangu, **Ciprian Tomuleasa**. *Frontiers in Medicine* 2025, **impact factor : 3.1**. manuscript in preparation.

PATIENT-CENTERED AND COORDINATED THERAPY WITH RNA INTERFERENCE-BASED GIVOSIRAN FOR ACUTE HEPATIC PORPHYRIA : REAL LIFE EXPERIENCE FOR AN ULTRA-RARE DISEASE FROM ROMANIA. Anamaria Bancos, Ciprian Jitaru, Andrada Uhl, Diana Roibu, Diana Cenariu, Bogdan Tigu, Madalina Nistor, Raluca Munteanu, Maria Santa, Cristian Moldovan, Diana Gulei, Delia Dima, Maria Puiu, **Ciprian Tomuleasa**. *Blood Science* 2025, **impact factor : 2.7**, submitted for publication.

SPATIAL BIOLOGY OF CANCER OF UNKNOWN PRIMARY REVEALS ORIGIN, VULNERABILITIES, AND BIOLOGICAL PATHWAYS : A MULTICENTER RETROSPECTIVE STUDY. Marta Casado-Pelaez, Eva Musulen, Daniela Grases, Aleix Noguera-Castells, Abu Saadat, Oscar Gonzalez-Velasco, Javier De Las Ribas, Elena Perez, Thomas Breen, Jesus Rodriguez-Pascual, Marcial Garcia-Rojo, Marius Ilié, Paul Hofman, Alvaro Taus, Belen Lloveras, Miguel Angel Quintela, Victor Fumanal, Maria Angels Cañas-Tello, Angel Diaz-Lagares, Jorge Garcia-Gonzalez, Rafael Lopez, **Ciprian Tomuleasa**, Minodora Desmirean, Xavier Matias-Guiu, Montse Sanchez-Cespedes, Elisabetta Mereu, Eduard Porta-Pardo, Veronica Davalos, and Manel Esteller. *Cancer Research* 2025, submitted for publication, **impact factor: 16.6**.

INTEGRATING FLOW CYTOMETRY IN THE DIAGNOSTIC WORK OF HIV-ASSOCIATED HODGKIN'S LYMPHOMA. Maria Santa, Diana Cenariu, Adrian-Bogdan Tigu, Marc Damian, Patricia Rantshabeng, Andrada Uhl, Tendani Gaolathe, Andrew K. Ndlovu, Khalid Abdelrahman, Madalina Nistor, David Kegyes, Diana Gulei, Cristian Jinca, Vladimir-Petru Filip, Anamaria Bancos, Ioana Rus, Horia Bumbea, Victor Tomacinschii, Sanda Buruiana, Rand Bilal, Cristina Selicean, Mihnea Zdrenghea, Ion Antohe, Cosmin Minciuna, Mihnea-Eudoxiu Hurmuzache, Adrian Streinu-Cercel, Bogdan Fetica, Minodora Desmirean, Cristina Stefan, Jonathan Fromm, **Ciprian Tomuleasa**. JCO Global Oncology 2025, **impact factor: 3.0**, submitted for publication.

THERAPEUTIC ADVANCES IN THE TARGETING OF ROR1 IN SOLID CANCERS. Adrian Bogdan Tigu, Mihnea Micu, David Kegyes, Anamaria Bancos, Diana Cenariu, Madalina Nistor, Radu Tomai, Diana Gulei, Anca Buzoianu, Ioana Rus, Carlo M. Croce, Hermann Einsele, **Ciprian Tomuleasa**. Trials 2025, submitted for publication, **impact factor: 2.0**.

INTEGRATING VENETOCLAX-BASED TARGETED AND/OR IMMUNE THERAPIES IN CHRONIC LYMPHOCYTIC LEUKEMIA. David Kegyes, Ximena Muresan, Anamaria Bancos, Oana Mesaros, Horia Bumbea, Sanda Buruiana, Mihnea Zdrenghea, Alina Tanase, Carlo M. Croce, **Ciprian Tomuleasa**. Critical Reviews in Oncology / Hematology 2025, submitted for publication, **impact factor: 5.6**.

SGR-1505, A CLINICAL-STAGE MALT1 INHIBITOR, RESPONES NF-KB SUPRESSION AND OVERCOMES BTK RESISTANCE IN B-CELL MALIGNANCIES. Min Ye, Sen Zhang, Frank Basile, Brian Yoo, Wenxin Zheng, Evan Paull, Lin Tang, Jo Ta, Steven Pirie-Shepherd, Netonia Marshall, Stephen Spurgeon, Vincent Ribrag, Vasile Musteata, Oksana Karnabeda, Mengyang Di, Nashat Gabrail, Guru Subramanian Guru Murthy, Laura Calustian, Erin Mulvey, Matthew Ulrickson, **Ciprian Tomuleasa**, Carlo Visco, Adam Olszewski, Zhe Nie, Hamish

Wright, Margaret Dugan, Karen Akinsanya, Wu Yin. Science Translational Medicine 2025, submitted for publication. **impact factor : 14.6.**

REGIONAL DIFFERENCES IN HIV-ASSOCIATED LYMPHOMA OUTCOMES : EASTERN EUROPE VERSUS AFRICAN COHORTS. Maria Santa, Marc Damian, Patricia Rantshabeng, Cristina Dudnic, Andrada Uhl, Tendani Gaolathe, Andrew K. Ndlovu, Khalid Abdelrahman, Cristian Jinca, Vladimir-Petru Filip, Sanda Buruiana, Maria Robu, Adrian Bogdan Tigu, Ivan Negara, Daniela Galea-Absusa, Oleg Arnaut, Dumitru Brinza, Ina Scifos, Victor Tomacinschii, Radu Tomai, Delia Dima, Ioana Rus, Mihnea Zdrenghea, Anamaria Bancos, Ion Antohe, Cosmin Minciuna, Mihnea-Eudoxiu Hurmuzache, Adrian Streinu-Cercel, Bogdan Fetica, Minodora Desmirean, Cristina Stefan, **Ciprian Tomuleasa**. Journal of Cellular and Molecular Medicine 2025, submitted for publication. **impact factor : 4.2.**

AN EARLY-PHASE STUDY OF SGR-1505 AN ORAL MALTS1 INHIBITOR FOR RELAPSED/REFRACTORY B-CELL MALIGNANCIES. Stephen Spurgeon, Vasile Musteata, Oksana Karnabeda, Mengyang Di, Nashat Gabrail, Nashat Gabrail, Laura Calustian, Guru Subramanian Guru Murthy, Erin Mulvey, Vincent Ribrag, Michal Taszner, **Ciprian Tomuleasa**, Carlo Visco, Paolo Ghia, Erika Ravelli, Daniel Morillo Giles, David Stenehjem, Wu Yin, Allison Upalawanna, Sen Zhang, Christopher M Rubino, Sarsvat Patel, Vipul K. Gupta, Brian Yoo, Frank Basile, Margaret Dugan, Matthew Ulrickson, Adam Olszewski. Journal of Clinical Oncology 2025, submitted for publication. **impact factor : 42.1.**

METABOLIC – EPIGENETIC COUPLING : A HALLMARK OF MALIGNANT TRANSFORMATION. Adrian Bogdan Tigu, Andrei Ivancuta, Catalin Sorin Constantinescu, Olga Grajdieru, Ciprian Cucoreanu, Madalina Nistor, David Kegyes, Anamaria Bancos, Alina Tanase, Diana Gulei, **Ciprian Tomuleasa**. Discover Oncology 2025, submitted for publication. **impact factor : 2.9.**

TWICE WEEKLY LOW DOSE DECITABINE VERSUS AZACYTIDINE PLUS VENETOCLAX IN THE FRONTLINE OF ACUTE MYELOID LEUKEMIA, INELIGIBLE FOR INTENSIVE THERAPY. Radu Tomai, Ciprian Jitaru, Andrada Uhl, Anamaria Bancos, Oana Mesaros, Laura Jimbu, Sabina Iluta, Marc Damian, Szilard Biro, Delia Soare, Ion Antohe, Laura Oprescu, Maria Santa, Julia Zaharia, David Kegyes, Anna Marie Schwanthaler, Selin Defne Kaya, Samuel Michel Abaya, Delia Dima, Ioana Rus, Horia Bumbea, Mihnea Zdrenghea, Gabriel Ghiaur, **Ciprian Tomuleasa**. JCO Global Oncology 2026, submitted for publication. **impact factor : 3.3**

HOW WE USE LONCASTUXIMAB TESIRINE IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN THE REAL-LIFE SETTING. Mihnea Micu, Anamaria Bancos, Ciprian Jitaru, Marc Damian, Andrada Uhl, Bogdan Borlea, Tunde Torok-Vistai, Maria Santa, Radu Tomai, David Kegyes, Delia Dima, Mihnea Zdrenghea, Ioana Rus, **Ciprian Tomuleasa**. Frontiers in Pharmacology 2025, submitted for publication. **impact factor : 4.8**.

MIM8 PROPHYLAXIS OVER 52 WEEKS IN ADOLESCENTS IN ADULTS WITH HAEMOPHILIA A : A FRONTIER2 EXTENSION STUDY. Victor Jiménez-Yuste, Aby Abraham, **Ciprian Tomuleasa**, Hazza Alzahrani, Lize van Vulpen, Renchi Yang, Samya Obaji, Sanjay Ahuja, Sophie Susen, Steven Lentz, Amalie Rhode Høgh Nielsen, Ilgiz Rakhmatullin, Cédric Hermans. Research and Practice in Thrombosis and Haemostasis 2026, submitted for publication. **impact factor : 3.4**.